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THE ROLE OF CHEMERIN IN HELICOBACTER PYLORI INDUCED 
GASTRIC PATHOGENESIS 
SUMMARY 
Helicobacter pylori (H. pylori) is a gram negative, spiral –shaped, microaerophilic, 
flagellated bacterium which colonize in the human gastric epithelium and is 
classified as type I carcinogen for association with the development of gastric 
malignancies such as chronic gastritis, gastric adenocarcinoma, peptic ulcers and 
gastric lymphoma. Although 50% of the world’s population is infected with 
Helicobacter pylori, the majority of infections do not lead to symptoms or 
gastrointestinal disease due to the pathogen’s unique ability to avoid strong innate 
and adaptive immune responses. The bacteria are rarely eliminated, colonization 
usually persists throughout life, and infection involves both innate and adaptive 
immune responses. 
Chemerin is a protein from cathelicidine/cystatin family and the major ligand of G 
protein coupled receptor CMKLR1 (chemokine like receptor 1). It is present in 
various tissues including epithelial cells, liver, spleen, lymph nodes etc. and 
promotes chemotaxis of leukocyte populations that express CMKLR1, such as 
macrophages, plasmacytoid dendritic cells and natural killer (NK) cells to site of 
inflammation. It is ubiquitously found in plasma as 143 amino acids prochemerin at 
nanomolar concentrations and becomes activated into various isoforms through 
proteolytic cleavage by a myriad of serine and cysteine proteases as well as 
carboxypeptidases. Chemerin promotes both pro- and anti-inflammatory immune 
response based on the stimuli provided and the disease being investigated. 
Inflammatory diseases, such as erythematosus, rheumatoid arthritis, psoriasis, 
Crohn’s disease showed association of elevated chemerin in inflammation 
development which is also observed in several mice and human studies. CMKLR1 
knockout mice showed reduced CNS inflammation in EAE and pulmonary 
inflammation in COPD (cigarette smoke- induced chronic obstructive pulmonary 
disease) model, suggesting a pro-inflammatory role of chemerin. However, anti-
inflammatory response was also observed when chemerin was discarded and in 
CMKLR1 knockout mice in LPS-induced lung injury and acute viral pneumonia with 
reduced expression of pro-inflammatory markers. 
Macrophages are plastic and heterogenic group of cells, which can polarize 
according to stimuli and the local microenvironment and shape the local 
inflammatory status to adapt to outside stimuli. Macrophages can be polarized into 
the classically activated -M1 type- macrophages and the alternatively activated -M2 
type- macrophage subsets. M1 type macrophages are the pro-inflammatory effector 
cells in innate immune response produced by granulocyte macrophage stimulating 
factor (GM-CSF), lipopolysaccharide (LPS) and IFN-g and secrete pro-inflammatory 
cytokines, such as TNF-a, IL-1b, IL-6, IL-12/ IL-23. The antimicrobial functions of 
M1 macrophages are linked to up-regulation of inducible nitric oxide synthase 
(iNOS) that generates nitric oxide from L-arginine and substantial production of NO. 
xxiv 
 
M2 type macrophages work in immunosuppression and tissue repair, produced by 
IL-4/IL-13 or M-CSF and secrete IL-10 and IL-1RA and low expression of IL-12/ 
IL-23. They do not produce NO. M2 macrophages can be further divided into subsets 
based on their cytokine expression profiles; M2a, M2b, and M2c.  
There are several studies regarding effects of H. pylori on macrophages. In early 
studies, it has been shown that H. pylori induces the expression of inducible NO 
synthetase (iNOS) from macrophages along with pro- inflammatory cytokines such 
as IL-6, IL-8, TNF-α, IL-1-β. However, alternatively activated M2 macrophages 
were detected in human gastric biopsy specimens from H. pylori positive individuals. 
Also, upon H. pylori infection, human monocytes secreted IL-1b, IL-6, IL-10, and 
IL-12p40 (partially secreted as IL-23), but not IL-12p70. Furthermore, cytokines 
secreted from innate immune cells, antigen presentation from macrophages and 
dendritic cells and changes in the microenvironment, also activates the adaptive 
immune response against H. pylori. Macrophage mediated pro-inflammatory Th1 
and Th17 response was observed as the pre-dominant adaptive response against H. 
pylori in humans. 
Chemerin/chemerin receptor signaling mediates chemotaxis and adhesion of 
macrophages to extracellular matrix proteins and endothelial cells through increased 
promotion of integrins clustering (VLA-5 and VLA-4). ChemR23-dependent anti- 
inflammatory and protective effects of chemerin was found in mice, whereas in 
humans LPS, TNF-alpha and IFN-gamma stimulation increased ChemR23 
expression in monocytes and macrophages which is associated with chronic and 
systemic inflammation. Macrophages may also exert pro- or anti-inflammatory 
response to different chemerin isoforms. Chemerin was observed to suppress M2 
macrophage polarization with increased pro-inflammatory cytokine profile in DSS 
induced colitis model in vivo and in vitro. Another study found increased chemerin 
expression on M1 macrophages with distinct IL-10 expression, explaining the 
inflammatory effect of chemerin on M1 macrophages. Marked expression of 
chemerin was shown to be produced by intestinal epithelial cells (IECS) which is 
involved in the continuous recruitment of macrophage precursors to 10-24 week fetal 
intestine and boosted the host defence mechanism and mucosal immunity in 
neonates. However, only fetal IECs but not mature IECs, produces chemerin. 
Many studies work on the effects of H. pylori on macrophages and gave valuable 
insights, there are studies that investigated the inter-relation between chemerin and 
macrophages as well. However, no studies have yet investigated the effect of 
chemerin on the polarization status of macrophages in H. pylori induced 
pathogenesis. It is known from the literature that H. pylori could potentially induce 
both M1 and M2 macrophages in human but how/whether chemerin could effect this 
inter-relation is not known. Therefore, in this study, we investigated the effect of 
both chemerin and H. pylori on the monocytic cell line THP-1 and observe the 
differences on its polarization status according to cytokine profiles. 
It was known from the literature that epithelial cells secrete chemerin. In order to 
observe the effect of chemerin on gastric immunopathology, it’s expression was first 
investigated on three gastric epithelial cell lines; KATO III, AGS and MKN45. 
Conventional PCR results revealed expression of chemerin in different levels by 
these cell lines. Next we evaluated the effect of H. pylori on chemerin expression by 
these cell lines. In order to do that, KATO III. AGS and MKN45 cells were treated 
with two H. pylori sonicates, the wild type G27 strain sonicate and its ΔcagA mutant 
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sonicate. The H. pylori virulence factor Cag A (cytotoxin- associated gene-A) was 
chosen since its association with development of gastric malignancies have been 
reported. Chemerin expression was signifantly increased in KATO III and AGS cell 
line when they were treated with wild type G27 and ΔcagA mutant sonicate for 6 and 
24 hours. After 24 hours, the expression level of chemerin reduced. No significant 
expression was observed on MKN45 cell line. Therefore, the following experiments 
were performed on KATO III and AGS cell lines. Next, we assess if chemerin 
protein expression was also increased along with the mRNA expression upon H. 
pylori treatment. Repeated attempts of western blot optimization experiments failed 
to show any expected band of chemerin in any treated or untreated groups of any cell 
line. To clarify if the lack of detection is real or due to inefficient antibody binding to 
chemerin, human chemerin was cloned and transfected into HEK293T cell line. 
Western blot was performed using various samples from different cell lines with 
different treatments and chemerin-expressing HEK293T cells. Chemerin was only 
detected in the whole cell extract of chemerin-transfected HEK293T cell lines but 
not in other samples. As a conclusion, we could detect elavated chemerin in mRNA 
levels upon H. pylori treatment but not in protein level.  
Next, we investigated expression of chemerin in gastric biopsy specimens of H. 
pylori positive patients of acute gastritis and chronic ulcer and compared it to 
uninfected patients without pathology. Real-time PCR experiments revealed presence 
of significantly higher levels of chemerin in ulcer patients. Of note, chemerin mRNA 
expression in samples from patients with gastritis was not significantly different 
when compared to control group. These data was supported by the results obtained 
from immunohistochemistry analysis performed on gastric tissues of H. pylori 
postive patients of acute gastritis, chronic ulcer and H. pylori  negative healthy 
individiuals. Chemerin was shown to be highly expressed in gastric tissues of ulcer 
patients. 
We investigated effects of chemerin on the polarization status of macrophages. For 
that, a monocytic cell line THP-1 was used and PMA (phorbol 12-myristate 13-
acetate) was administered to induce differentiation of monocytes into macrophages. 
The differentiated macrophages were then exposed to different stimuli such as LPS 
and recombinant IL-4 to polarize them into M1 and M2 subtypes respectively, with 
or without the presence of chemerin. The presence of macrophage specific markers 
were used to show the differentiation of monocytes into macrophages. Also, cytokine 
levels were measured by conventional PCR. Two pro-inflammatory cytokines 
namely IL-1β and IL-6 were used as a marker for M1 macrophages. Both of them 
were significantly increased in LPS- treated samples. When chemerin was 
administered with LPS, a significantly high expression of IL-1β and low expression 
of IL-6 observed when compared to LPS- treated sample only in the first set. Initially 
it was thought chemerin might have a role in the polarization of M1 macrophages but 
three repeated experiments showed no difference in the expression of IL-1β and IL6 
in samples treated with LPS alone or with chemerin. This disproves the possible 
effect of chemerin on M1 polarization. IL-10 expression was assessed to detect M2 
polarization. IL-4 treatment resulted in elevated IL-10 expression compared to 
control group and treatment of chemerin along with IL-4 diminished this expression. 
This is parallel with the study performed by Lin et al. (2014) where chemerin 
reduced the expression of M2 associated genes. 
Finally, we investigated the effect of H. pylori on the polarization of macrophages 
with or without the presence of chemerin to check whether chemerin may alter the 
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effect exerted by H. pylori on macrophages. The THP-1 macrophages were treated 
with wild type G27 and ΔcagA mutant sonicate with/without chemerin for 24 hours. 
The sonicate treatment polarized macrophages to M1 subtype with high profiles of 
pro-inflammatory IL-1β and IL6 and also increased IL-10. M1 macrophages are 
known to produce IL-10 in response to bacterial stimulation, this was also observed 
in a study on mice model stimulated by H. felis in our laboratory (unpublished data). 
However, no change of expression in IL-1β, IL6 and IL-10 was observed when 
chemerin was added with H. pylori sonicates. Therefore our results suggested 
chemerin may not have a role on effect of H. pylori induced M1 macrophage 
polarization, however M2 polarization was seen to be inhibited upon chemerin 
treatment which is H. pylori independent. 
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HELİCOBACTER PYLORİ İLE İNDÜKLENEN GASTRİK PATOGENEZDE 
KEMERİNİN ROLÜ 
ÖZET 
Helicobacter pylori (H. pylori), insan gastik epitelinde kolonize olan, gram negatif, 
spiral-şekilli, mikroaerofilik, kamçılı bir bakteridir. Bu bakteri, kronik gastrit, gastrik 
adenokarsinom, peptik ülserler ve gastrik lenfomalar gibi gastrik hastalıkların 
gelişimiyle olan bağlantısından dolayı Tip I karsinojen olarak sınıflandırılmaktadır. 
Dünya nüfusunun %50’si H. pylori ile enfekte olduğu halde, enfeksiyonların büyük 
bir çoğunluğu, patojenin güçlü doğal ve edinsel bağışıklık cevaplarından kaçınabilme 
yeteneğinden ötürü, semptomlara veya gastrointestinal hastalıklara yol 
açmamaktadır. Bakteriler nadiren tamamen yok edilir, kolonizasyon genel olarak 
ömür boyu sürer, ve enfeksiyon hem doğal, hem de edinsel bağışıklı cevaplarını 
içerir. 
Kemerin (chemerin), katelisidin/sistatin ailesinden bir proteindir ve G proteinine 
bağlı reseptör CMKLR1 ( kemokin benzeri reseptör 1)’in ana ligandıdır. Epitel 
hücreler, karaciğer, dalak, lenf düğümleri vb. dahil birçok dokuda mevcuttur. Bu 
şekilde, makrofajlar, plazmositoid dendritik hücreler ve NK hücreleri gibi CMKLR1 
ifade eden lökosit popülasyonlarının enflamasyon bölgesine kemotaksisini başlatır. 
Plazmada her yerde, sürekli, nanomolar konsantrasyonlarda 143 aa prokemerin 
olarak bulunan protein, serin ve sistein proteazlarının yanı sıra karboksipeptidazlar 
tarafından proteolitik kesime uğrayarak, farklı formlar halinde aktive olur. Kemerin, 
ortamdaki uyarıcıya ve incelenen hastalığa göre, hem pro-enflamatuvar, hem de anti-
enflamatuvar cevaplara sebep olabilmektedir. Eritematöz, romatoid artrit, psöriyazis 
(sedef hastalığı), Crohn hastalığı gibi enflamatuvar hastalıklarda, birçok kobay ve 
insan çalışmalarında da gözlemlendiği gibi, enflamasyon gelişiminde artan kemerin 
seviyelerinin hastalıklarla ilişkisi gösterilmiştir. CMKLR1 nakavt farelerde, EAE’de 
merkezi sinir sistemi (MSS) enflamasyonunun ve sigara içmeye bağlı kronik 
obstrüktif akciğer hastalığı (KOAH) modelinde pulmoner enflamasyonun azaldığı 
gösterilmiştir. Bu şekilde, kemerinin pro-enflamatuvar rolü ortaya konmuştur. Fakat, 
LPS ile akciğer hasarlı modelde ve pro-enflamatuvar markerlerin ifadesi azaltılmış 
akut viral pönomi modelinde, CMKLR1 nakavt farelerde ve kemerinin baskılandığı 
durumlarda, kemerinin anti-enflamatuvar rolü de gözlemlenmiştir. 
Makrofajlar, dışarıdan gelen uyarılara adapte olmak için yerel enflamatuvar 
durumlarını şekillendirebilen, uyarana ve yerel mikroçevreye göre polarize olabilen, 
plastik ve heterojenik bir hücre grubudur. Makrofajlar, klasik yollardan aktive olan- 
M1 tipi-makrofajlara ve alternatif yollardan aktive olan –M2 tipi-makrofaj alt 
gruplarına polarize olabilmektedir. M1 tipi makrofajlar, granülosit makrofaj uyarıcı 
faktör (GM-CSF), lipopolisakkarit (LPS) ve IFN-g tarafından üretilen doğal 
bağışıklık cevapta görülen, pro-enflamatuvar efektör hücrelerdir ve TNF-a, IL-1b, 
IL-6, IL-12/ IL-23 gibi pro-enflamatuvar sitokinler salgılarlar. M1 tipi makrofajların 
antimikrobiyal fonksiyonları, L-argininden nitrik oksit ve çok miktarda NO üreten, 
indüklenebilir niktik oksit sentazın (iNOS) ifadesinin artmasına bağlıdır. M2 tipi 
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makrofajlar ise, IL-4/IL-13 veya M-CSF ile üretilen, immün baskılama ve doku 
tamirinde görev alan, IL-10 ve IL-1RA salgılayıp, düşük seviyelerde IL-12/ IL-23 
ifade eden hücre gruplarıdır. Bu hücreler, NO üretmezler. M2 tipi makrofajlar, 
sitokin ifade profillerine göre kendi içlerinde M2a, M2b, ve M2c olmak üzere alt 
gruplara ayrılırlar. 
H. pylori'nin makrofajlardaki etkileri ile ilgili birkaç çalışma mevcuttur. İlk 
çalışmalarda, H. pylori'nin makrofajlarda IL-6, IL-8, TNF-α, IL-1-β gibi pro-
enflamatuvar sitokinlerle birlikte indüklenebilir NO sentetaz (iNOS) enziminin 
ekspresyonunu  indüklediği gösterilmiştir. H. pylori pozitif bireylerden alınan gastrik 
biyopsi örneklerinde alternatif olarak aktive olan M2 makrofajlar gözlenmiştir. 
Ayrıca, H. pylori enfeksiyonu durumunda insan monositleri, IL-1b, IL-6, IL-10 ve 
IL-12p40 (kısmen IL-23 olarak salgılanan) salgılarken IL-12p70 sitokini 
salgılamamıştır. Bununla beraber, doğal immün sistem hücreleri tarafından 
salgılanan sitokinler, makrofajların ve dendritik hücrelerin antijen sunması ve 
mikroçevredeki değişimler, H. pylori'ye karşı sonradan kazanılmış immün cevabı 
aktive eder. İnsanlarda H. pylori'ye karşı makrofaj aracılı pro-enflamatuvar Th1 ve 
Th17 immün cevap hakimdir. 
Kemerin/kemerin reseptör sinyalleşmesi, artan integrin kümelenmesi yoluyla (VLA-
5 ve VLA-4) kemotaksise ve makrofajların hücre dışı matriks proteinlerine ve 
endotelyal hücrelere adhezyonuna aracılık eder. Farelerde kemerinin ChemR23-
bağımlı anti-enflamatuvar ve koruyucu etkileri gözlenmiştir. İnsanlarda ise LPS, 
TNF-a and IFN-g uyarımı, kronik ve sistemik enflamasyonla ilişkili olan 
monositlerde ve makrofajlarda ChemR23 ekspresyonunu artırmıştır. Ayrıca, 
makrofajlar farklı kemerin izoformlarına cevap olarak pro- ve anti-enflamatuvar 
yanıt oluşturabilir. Kemerinin DSS ile indüklenen kolit modelinde in vivo and in 
vitro koşullarda artan pro-enflamatuvar sitokin profilinin yardımıyla M2 makrofaj 
polarizasyonunu baskıladığı gözlenmiştir. Bir başka çalışmada M1 makrofajlarda 
belirgin IL-10 ekspresyonu ile birlikte artan kemerin ekspresyonun gözlenmesi 
kemerinin M1 makrofajlardaki enflamatuvar etkisini açıklamaktadır. Belirgin 
kemerin ekspresyonunun, makrofaj öncüllerinin 10-24 haftalık fetal bağırsakta 
sürekli olarak toplanmasında görev alan ve yeni doğanlarda konak savunma 
mekanizmasını ve mukozal bağışıklığı artıran intestinal epitel hücreler (IECler) 
tarafından gerçekleştirildiği gösterilmiştir. Fakat, olgun IEC'lerin aksine sadece fetal 
IEC'ler kemerin üretir. 
Makrofajlarda H. pylori'nin etkilerini araştıran birçok çalışma değerli görüşler ortaya 
koymuştur. Ayrıca, kemerin ve makrofajlar arasındaki ilişkiyi araştıran çalışmalar da 
mevcuttur. Fakat, H. pylori ile indüklenen patogenezde kemerinin makrofaj 
polarizasyonuna etkisini araştıran çalışmalar henüz yoktur. H. pylori'nin insanda 
potansiyel olarak M1 ve M2 tipi makrofajları indükleyebildiği bilinirken; kemerinin 
bu ilişkiyi nasıl etkileyebildiği bilinmemektedir. Dolayısıyla bu çalışmada, kemerin 
ve H. pylori'nin monositik hücre hattı olan THP-1 hücreleri üzerindeki etki ve bu 
hücrelerin sitokin profillerine göre polarizasyon durumları arasındaki farklılıklar 
araştırılmıştır. 
Literatürden epiteliyal hücrelerin kemerin salgıladıkları bilinmektedir. Kemerinin 
gastrik patolojideki etkisini gözlemlemek için, ilk olarak 3 gastrik epiteliyal hücre 
hattında (KATO III, AGS ve MKN45) kemerin ekspresyonu araştırılmıştır. Klasik 
PCR sonuçları kemerinin bu hücreler tarafından eksprese edildiğini göstermiştir. 
Daha sonra, H. pylori'nin bu hücre hatlarında kemerin ekspresyonuna etkisi 
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incelenmiştir. Bunu gerçekleştirmek için, KATO III, AGS ve MKN45 hücreleri 
yabani tip G27 suş sonikatı ve bu suşun ΔcagA mutant sonikatı ile olmak üzere 2 
ayrı H. pylori sonikatı ile muamele edilmiştir. H. pylori virulans faktörü CagA'nın 
(sitotoksin-ilişkili gen-A) gastrik kötü huylu tümörlerle ilişkisi gösterildiğinden, bu 
çalışma için CagA virulans faktörü seçilmiştir. Kemerin ekspresyonu, KATO III and 
AGS hücre hatlarında yabani tip G27 ve ΔcagA mutant sonikatları ile 6 ve 24 saat 
muamele edildiğinde önemli ölçüde artmıştır. Bundan sonra ise kemerin ifadesi 
azalmıştır. Ancak MKN45 hücre hattında anlamlı bir ifade gözlenmemiştir. Bu 
nedenle diğer deneylere KATO III and AGS hücre hatları ile devam edilmiştir. Daha 
sonra, H. pylori muamelesi ile mRNA ekspresyonunun yanı sıra protein ifadesinin de 
artıp artmadığı kontrol edilmek istenmiştir. Tekrarlı western blot optimizasyon 
deneyleri sonucunda, herhangi bir hücre hattının muamele edilen ve edilmeyen 
gruplarında kemerin bandı görülmemiştir. Bu sonuçların nedeninin protenin 
olmaması veya antikorun proteine yetersiz bağlanması olduğunun kararlaştırılması 
amacıyla, insan kemerini klonlanmış ve HEK293T hücre hattına transfekte 
edilmiştir. Tüm örnekler kullanılarak western blot gerçekleştirilmiştir ve kemerin 
sadece insan kemerin genini içeren plasmid ile transfekte edilen HEK293T nin tüm 
hücre ekstraktında tespit edilmiştir. Sonuç olarak, H. pylori muamelesinden sonra 
kemerin artışı mRNA seviyesinde tespit edilirken, protein seviyesinde 
görülememiştir. Daha sonra, H. pylori pozitif akut gastrit ve kronik ülser hastalarında 
da kemerin ekspresyonunu incelenmiştir ve patoloji göstermeyen enfekte olmamış 
hastalarla karşılaştırılmıştır. Real-time PCR deneyler, ülser hastalarında kemerinin 
anlamlı ölçüde fazla bulunduğunu göstermiştir. Gastrit hastalarının numunelerinde, 
kemerin mRNA ifadesinin, kontrol grubuyla anlamlı farklılıklar göstermediğine 
dikkat edilmelidir. Bu veriler, akut gastrit ve kronik ülserli H. pylori pozitif 
hastaların ve  H. pylori negatif sağlıklı bireylerin gastrik dokuları üzerinde yürütülen 
immünohistokimya analizlerinden elde edilen sonuçlar tarafından desteklenmektedir. 
Daha sonra, kemerinin makrofajların polarizasyon durumu üzerindeki etkilerini 
incelenmiştir. Bu amaçla, monositik bir hücre hattı olan THP-1 kullanılmış ve 
monositlerin makrofajlara farklılaşmasını indüklemek için PMA (phorbol 12-
myristate 13-acetate) ile muamele edilmiştir. Farklılaşan makrofajların M1 and M2 
alt tiplerine polarize olması için kemerin varlığında ve yokluğunda sırasıyla LPS ve 
rekombinant IL-4 gibi farklı uyaranlar eklenmiştir. Monositlerin makrofajlara 
farklılaştığını göstermek için makrofajlara özgü belirteçlerin varlığına bakılmıştır. 
Aynı zamanda, klasik PZR ile sitokin seviyeleri ölçülmüştür. IL-1β ve IL-6 pro-
enflamatuvar sitokinleri M1 tipi makrofajların belirteci olarak kullanılmıştır. Her 
ikisinin de LPS ile muamele edilen örneklerde anlamlı ölçüde arttığı 
gözlemlenmiştir. Kemerin, LPS ile uygulandığı zaman, yalnızca ilk setteki LPS ile 
muamele edilen örnekler ile karşılaştırıldığında IL-1β’nın anlamlı ölçüde yüksek 
ekspresyonu ve IL-6’nın düşük ekspresyonu gözlenmiştir. Başlangıçta, kemerinin 
M1 tipi makrofajlara polarizasyonunda bir etkisinin olabileceği düşünülmüştür, 
ancak tekrarlanan üç deney sadece LPS ile veya kemerin ile muamele edilen 
örneklerde IL-1β ve IL6 ekspresyonunda bir değişim olmadığını göstermiştir. Bu da, 
kemerinin M1 tipi hücrelere polarizasyona bir etkisinin olma olasılığını ortadan 
kaldırmıştır. M2 polarizasyonunu tespit etmek için IL-10 ekspresyonu 
değerlendirilmiştir. Kontrol grubu ile karşılaştırıldığında, IL-4 muamele edilen 
gruplarda IL-10’un ekspresyonu artış göstermiştir ve kemerinin IL-4 ile birlikte 
uygulanması bu etkiyi ortadan kaldırmıştır. Bu da, Lin vd. (2014) tarafından yapılan 
kemerinin M2 ile ilişkili genlerin ekspresyonunu azalttığı çalışmayı 
desteklemektedir.  
xxx 
 
Sonuç olarak,  yapılan çalışmada, H. pylori’nin makrofajlar üzerindeki etkisini 
değiştirip değiştirmediğini kontrol etmek için, kemerin varlığında ve yokluğunda, H. 
pylori’nin makrofaj polarizasyonu üzerideki etkisi incelenmiştir. THP-1 makrofajları 
kemerinin varlığı ve yokluğunda yabani tip G27 ve ΔcagA mutant sonikatları ile 24 
saat muamele edilmiştir. Sonikat muamelesi makrofajları yüksek IL-1β ve IL6 
üreten, pro-enflamatuvar profilindeki  M1 alt tipine polarize ederken IL-10’u da 
arttırmıştır. M1 makrofajlarının bakteriyal uyarımına cevap olarak IL-10 ürettiği 
bilinmektedir, bu durum ayrıca laboratuvarımızdaki diğer bir çalışmada H. felis ile 
uyarılan bir fare modelinde de gözlenmiştir (yayımlanmamış veri). Ancak,  H. pylori 
sonikatlar ile birlikte kemerin muamele edildiğinde IL-1β, IL6 ve IL-10 
ekspresyonunda hiçbir değişiklik gözlenmemiştir. Bu nedenle, sonuçlarımız, H. 
pylori ile indüklenen M1 makrofaj polarizasyonunda kemerinin bir rolü 
olmayabileceğini önermektedir, ancak M2 polarizasyonunun kemerin muamelesi ile 
H. pylori’den bağımsız şekilde engellendiği gözlemlenmiştir.    
 
 
1 
 INTRODUCTION  
1.1 Helicobacter Pylori 
Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, 
microaerophilic, slow-growing, spiral-shaped and flagellated bacterium usually 
reside in the gastric epithelium (Figure 1.1). In 1983, two Australian scientists named 
Barry Marshall and Robin Warren first discovered this human pathogen in gastric 
biopsies of a patient with chronic gastritis and gastric ulcers, conditions not 
previously believed to have a microbial cause [1]. 
 
Figure 1.1 : Scanning electron microscopy of Helicobacter pylori (from Yoshiyama 
& Nakazawa, 2000). 
Approximately 50% of the world’s population is infected with Helicobacter pylori, 
rendering it the most prevalent chronic bacterial infection of humans. It is typically 
transmitted via oral-oral, faecal-oral or gastro-oral exposures [2]. This pathogen can 
persevere for years in the gastric mucosa irrespective of prompting strong innate and 
adaptive immune responses via characteristic urease production, motility, and 
adherence to gastric epithelium. All these features enable it to neutralize gastric acid, 
penetrate through the mucus layer to the gastric epithelium, and colonize. 
H. pylori infection causes diseases of the upper gastrointestinal tract such as chronic 
gastritis, poses a major threat for the development of peptic ulcer disease (PUD)  and 
gastric malignancies such as gastric marginal zone/mucosa-associated lymphoid 
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tissue (MALT) and gastric adenocarcinoma (Figure 1.2) [3]. In addition to its 
association with cancer, this organism has also been recently found to be involved 
with extraintestinal diseases, such as immune thrombocytopenic purpura, refractory 
iron deficiency anaemia and vitamin B12 deficiency [4]. While infection with H. 
pylori perseveres without treatment, the majority of infections do not lead to 
symptoms or gastrointestinal disease. 
 
Figure 1.2 : Progression of H. pylori infection towards carcinoma (Adapted from 
Vincenza et al., 2013). 
The growing rate of antibiotic resistance and the declining rates of antimicrobial 
eradication pose an alarmingly critical situation worldwide, from 80% in the early 
1990s to as low as 60% in some countries at present [5]. There is a yearly occurrence 
of 0.3- 0.7% and 6-14% H. pylori infection estimated in developed and developing 
countries respectively [6]. A cohort study in 207 H. pylori-negative individuals 
recognized four new infections (2.5%), comparing to an annually 0.25% (0.10-0.63) 
prevalence rate [7].  
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1.1.1 Genome 
The two independent H. pylori genomes that have been completely sequenced have 
distinct origins, H. pylori 26695 isolated from a gastritis patient and H. pylori J99 
isolated from a patient suffering from a duodenal ulcer and duodenitis [8]. The H. 
pylori 26695 strain is a circular chromosome with 1,667,867 base pairs (bp) that has 
39% average G+C content. Within the genome different G+C composition is shown 
in five regions (Table 1.1) . Two of these regions encompass genes involved in DNA 
processing. One region has 2 orthologues of the virB4/ptl gene, which is required for 
the transfer of oncogenic T-DNA of Agrobacterium and the secretion of the pertussis 
toxin by Bordetella pertussis [9] and therefore crucial. Another region is known as 
cag pathogenicity island (PAI), which is flanked by 31-bp direct repeats, and appears 
to be the product of lateral transfer [10]. 
Table 1.1 : G + C Regions present in H. pylori genome with associated genes 
(Adapted from Jean-F. & Owen et al., 1997). 
Distinct G+C Regions Associated Genes 
Region 1 (33% G+C) 452-479 kb IS605, 5SRNA and repeat 7; virB4 
Region 2 (35% G+C) 539-579 kb cagPAI 
Region 3 (33% G+C) 1,049-1,071 kb IS605, 5SRNA and repeat 7 
Region 4 (33% G+C) 1,264-1,276 kb β and β’ RNA Polymerase, EF-G (fusA) 
Region 5 (33% G+C) 1,590-1,602 kb Two restriction/modification systems 
1.1.2 Virulence factors of Helicobacter pylori 
The major virulence factors of H. pylori are the cytotoxin-associated gene 
(cag) pathogenicity island (PAI)-encoded virulence factors, such as the cytotoxin-
associated antigen (CagA) protein, the vacuolating toxin-A (VacA), the blood group 
antigen-binding adhesin (BabA) and the outer inflammatory protein (OipA). This 
would be further discussed into the next section. 
Adhesion molecules are necessary for the adherence of bacteria to host cells as well 
as for the colonization in human stomac. H. pylori adherence molecules belong to 
Hop family and are the members of outer membrane protein (OMP) family. Hop 
family includes BabA (blood group antigen binding adhesion), OipA (the outer 
inflammatory protein A), SabA & B (sialic acid-binding adhesion), HopZ and 
AlpA/B (Figure 1.3) [11]. Apart from H. pylori virulence factors and adhesion 
molecules, flagella, LPS (lipopolysaccharides), peptidoglycan (PGN), HP-NAP, 
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IceA, DupA, superoxide dismutase, catalase, and protease enzymes may play a role 
in progression and severity of diseases. 
 
Figure 1.3 : Virulence factors of H. pylori and their functions (adapted from Nina et 
al., 2013). 
1.1.2.1 The Helicobacter pylori cagPAI  
The cag Pathogenicity Island (cagPAI) was first identified in 1996. cagPAI is a 40 kb 
DNA insertion element and includes approximately 31 genes. cagPAI is present in 
60-70% of Western H. pylori strains and approximately 100% of East –Asian H. 
pylori strains [12]. This island encodes a type IV secretion system (T4SS) which is 
required for bacterial conjugation and translocation of bacterial effector proteins into 
the host gastric epithelial cells [13,14]. Helicobacter pylori uses T4SS injection 
apparatus for translocation of Cag A protein and peptidoglycans (PGNs) into the host 
cell [15]. CagPAI contains several virulence factors such as Cag A, Cag E, Cag L, 
Cag Y, and Cag I [16]. 
Cag E helps in translocation and phosphorylation of Cag A protein and mediates the 
production of proinflammatory cytokines such as IL-8 (Interleukin-8) (neutrophil-
activating chemokine) through NF-κB (Nuclear Factor -kappa B) pathway [17]. Cag 
L, located at the surface of the pilus, has a specific Arginine-Glycine-Aspartate 
(RGD) motif which is recognized by the integrin receptor on the target epithelial cell. 
CagL helps translocation of Cag A protein into the cytoplasm of host cell [18]. Also, 
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CagL activates host Src and host focal adhesion kinase (FAK) for phosphorylation of 
Cag A protein. Cag Y virulence factor is found at the pilus and both Cag Y and Cag I 
are required for Cag A translocation. 
1.1.2.2 Secreted toxins of Helicobacter pylori    
H. pylori strains secret several toxins to perform various functions necessary for 
prolonged persistence. VacA (Vacuolating Cytotoxin A), a pore-forming toxin, is 
carried by all H. pylori strains that interrupts cell polarity, stimulates apoptosis of 
epithelial cells and prevents T cell proliferation and effector functions. Sequence 
variation in several domains of VacA results in varying levels of expression, cell 
type-specific toxicity as well as disease severity [19].  
CagA, another important toxin of H. pylori, has been regarded as a bacterial 
oncoprotein for its association with an increased risk of cancer and inducing gastric 
carcinoma and other malignancies in transgenic mice. This 120-140 kDa protein was 
initially isolated as an immunodominant antigen from patients infected with highly 
virulent vacA alleles [41]. CagA translocates into host cells with the aid of Cag T4SS 
which is encoded on the cag pathogenicity island (PAI) [1,20] (Figure 1.3). 
CagA oncoprotein has repeated sequences in its 3’ region consisting of Glutamine- 
Proline- Isoleucine- Tyrosine- Alanine (EPIYA) motifs and these motifs include a 
tyrosine phosphorylation site. After translocation into host cells, CagA can be 
tyrosine phosphorylated and interacts with SHP2 tyrosine phosphatase and CSK 
kinase. Unphosphorylated CagA is known to interact with CRK adaptor, MET, 
growth factor receptor-bound protein 5 (GRB5), PAR1 (also known as MARK) and 
E-cadherin (Figure 1.4). These interactions lead to altered cell signalling and changes 
in cell polarity, extrusion, motility, proliferation and pro-inflammatory cytokine 
secretion [1,20]. 
1.1.3 Helicobacter pylori colonization in gastric mucosa 
Unlike any other pathogen, H. pylori has a distinct ability to inhabit in an extremely 
acidic environment. After entering into gastric milieu by oral ingestion, it is promptly 
exposed to the extreme pH in the lumen side of the gastric mucous layer (pH ≅2). 
The survival of H. pylori in such adverse environment depends on the following 
mechanism. 
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Figure 1.4 : Interaction of CagA and VacA virulence factors with gastric epithelial 
cells and the immune system, resulting in an inflammatory response and mucosal 
damage (Adapted from Vincenza et al., 2013). 
1.1.3.1 Escape from the acidic lumen 
In order to survive H. pylori must escape from the acidic stomach lumen and migrate 
to its usual habitation in the gastric epithelium. This is achieved by bacterial urease 
that aids in acid resistance through the localized production of ammonium ions. 
Gastric mucins form a gel at low ph to trap microbes efficiently in the lumen. These 
ammonium ions aid in flagellar motility via raising the pH to near neutral and the 
mucous gel transitions to a viscoelastic solution through which H. pylori can swim 
[21,22]. 
Other than assisting in clearance, H. pylori infection associates with less 
inflammation, less CD4+ T cells recruitment and a lack of T helper 17 (TH17) 
response [23] hence supporting stable infection while at the same time aggravating 
more inflammation. Based on the observation that increased inflammation often 
associates with lower bacterial loads [24], it is suggested that H. pylori must actively 
maintain its interaction with the host epithelium to avoid clearance and survive. 
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1.1.3.2 Persistent colonization of the gastric mucosa 
Detoxification of reactive oxygen species (ROS) is a crucial step for the survival of 
H. pylori. H. pylori derived catalase, superoxide dismutase and arginase control nitric 
oxide produced by nitric oxide synthase from macrophages, neutrophils and 
epithelial cells [25].  Furthermore, DNA repair pathways have also shown to be able 
to support bacterial colonization efficiently even when the neighboring host tissue 
accrues DNA lesions [26]. 
Additionally, H. pylori strains constitutively express DNA repair proteins such as 
RecA. After DNA damage, H. pylori upregulates natural competence instead, 
promoting chronic perseverance possibly via enhanced genetic diversification [27]. 
The H. pylori genome encompasses numerous intragenic and extragenic repeat 
sequence. For example, cell surface protein CagY, which promotes type IV secretion 
system (T4SS)-mediated translocation of the effector CagA, can undergo 
recombination between internal repeat motifs that generally preserve the reading 
frame [28]. 
1.1.4 Evasion Of innate immune recognition 
The key to the success of the bacterium for prolonged inhabitation in host gastric 
mucosa lies in the development of intricate tactics to avoid and undermine host 
immune defense mechanism. The first defense barrier against H. pylori is the mucus 
produced by the epithelial cells lining the gastric mucosa and the innate immune cells 
that either dwell in the gastric lamina propria under steady state conditions or are 
recruited there during infection. Epithelial cells as well as innate immune cells detect 
conserved pathogen-derived molecular structures or PAMPs (pathogen-associated 
molecular patterns) on pathogent via pattern recognition receptors (PRRs). H. pylori 
evades recognition by several types of PRR critical for the identification of other 
Gram-negative enteropathogens. 
1.1.4.1 H. pylori mediated evasion and manipulation of Toll-like receptors 
(TLRs) recognition  
Toll-like receptors (TLRs) are single, membrane-spanning, non-
catalytic receptors usually expressed by macrophages and dendritic cells that 
recognize PAMPs from microbes.  
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Figure 1.5 : H. pylori mediated evasion from Innate immune response (Adapted 
from Nina et al.; 2013). 
H. pylori mainly escapes from recognition by TLR4, which recognizes 
Lipopolysaccharides or LPS found in outer membrane of Gram- negative bacteria 
(Figure 1.5). H. pylori produces 1,000-fold less active LPS than hexa-acylated E. coli 
LPS via removal of phosphate groups from the backbone of lipid A. The outcome is 
tetra-acylated LPS with less negative charge that resists antimicrobial peptides 
attachment (such as polymyxin B) and avoids detection by TLRs [29]. They 
frequently express LPS O antigens structurally similar to human Lewis blood group 
antigens (Monteiro et al., 1998; Aspinall & Monteiro, 1996). Such resemblance to 
“self” antigens enables them in molecular mimicry or immune tolerance and 
protection from immune recognition [30]. 
It also escapes recognition by TLR5 through the modifications in the N-terminal 
TLR5 recognition domain of Flagellin [31]. H. pylori infection activates endosomal 
TLR9 in an anti-inflammatory fashion has been observed in a mouse model (Figure 
1.5) [32].  
This has been supported in a study conducted by Sayi et al. (2011) on Tlr2 knock out 
mice, when infected with H. felis (pathogen of domestic animals) showed stronger T 
cell responses and T cell-driven immune response with better infection control. The 
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effects of TLR2 gene deletion are phenocopied by Myd88−/− mice, indicating that 
the absence of anti- inflammatory signals induced by Helicobacter spp. is 
phenotypically dominant over the simultaneous lack of MYD88-dependent pro-
inflammatory signals that are induced by other TLRs [33]. 
1.1.4.2 Suppression of CLR-mediated signalling 
H. pylori infection also mediates an anti-inflammatory response by suppressing DC-
SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin), or CD209, a C-type lectin receptors (Figure 1.5). The fucose residues 
present on the ligand for DC-SIGN efficiently remove a signaling complex from DC-
SIGN [34]. The signaling complex consists of scaffold proteins LSP1, KSR1 and 
CNK and the kinase RAF1, causing DC-SIGN- and RAF1-mediated activation of 
NF-κB, which prolongs and increases IL-10 transcription [35] 
Briefly, H. pylori suppresses strong pro-inflammatory response and escapes from 
consequential adaptive immunity and clearance, via two main mechanisms: by 
avoiding pro-inflammatory TLRs driven innate immune detection and the superior 
activation and manipulation of anti-inflammatory TLRs and CLRs. Together, these 
approaches promote the persistence of the organism. 
1.1.5 Modulation of effector T cell responses 
1.1.5.1 Suppression of Th1- and Th17-mediated immunity 
The association of two virulence factors, VacA and GGT in the manipulation and 
inhibition of human T cell response was reported. VacA impedes IL-2 mediated T 
cell proliferation pathway. It inhibits Ca2+/calmodulin-dependent phosphatase 
calcineurin [36], necessary for the nuclear import of NFAT, an important 
transcription factor for T cell mediated immune response. An adhesion molecule 
LFA1 (αLβ2 integrin) present on the T cell is exploited by H. pylori to promote 
uptake of VacA. β2 integrin, a component of the LFA1 has been identified as a 
receptor for VacA [37] that undergoes serine/threonine phosphorylation on the 
cytoplasmic tail and facilitates VacA uptake [38]. 
GGT interrupts the RAS signalling pathway and inhibits cyclin-dependent kinase 
activity in the G1 phase of the cell cycle, therefore blocks T cell proliferation [39]. 
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1.1.5.2 Skewing of T cell responses 
In order to respond to a pathogenic infection, ‘tolerogenic’ dendritic cells have to 
encounter first to the pathogen and then initiate differentiation in naive T to mediate 
TH1 and TH17 effector T cell response. However, H. pylori exposed Dendritic cells 
fail to produce effector T cell responses both in vitro and in vivo. Instead they 
stimulate the expression of regulatory T cell specific transcription factor FOXP3, the 
surface marker CD25 and the anti-inflammatory cytokine IL-10 in naive T cells [40]. 
H. pylori-specific memory T cell responses has been severely compromised by such 
TReg cells accumulated in H. pylori- infected human gastric mucosa [41]. 
Such H. pylori-specific tolerance to dendritic cells requires the activity of both VacA 
and GGT [42], although the exact mechanism by which VacA- and GGT- achieved 
such tolerance remains unclear. 
1.2 Chemerin 
Chemerin, primarily known for its chemotactic and adipokine properties, is 
structurally related to the cathelicidin/cystatin family of proteins, was first discovered 
in psoriatic lesions of the skin in the late nineties. This multifunctional protein was 
transcriptionally upregulated by the anti- psoriatic synthetic retinoid tazarotene, 
therefore initially named as tazarotene-induced gene 2 protein (TIG2) or retinoid acid 
receptor responder 2 (RARRES2)[43].    
A few years later chemerin was rediscovered as a ligand for the orphan seven-pass 
transmembrane receptor chemokine-like receptor 1 or CMKLR1 through G protein-
associated receptor screening assays [44]. CMKLR1 (also known as ChemR23, DEZ, 
and finally renamed “chemerin receptor” by the International Union of Basic and 
Clinical Pharmacology) is expressed by several immune cell subsets (plasmacytoid 
dendritic cells (pDCs), macrophages and NK cells) that respond to chemerin either 
through chemotaxis or modulation of their defense function [45].  
It is widely expressed and secreted as a 143-aa (chemerin 20–163) precursor protein 
(prochemerin) with low biological activity and ubiquitously found in plasma at 
nanomolar concentrations. It can be converted to a variety of isoforms with different 
functions through proteolytic cleavage by a myriad of serine and cysteine proteases 
as well as carboxypeptidases [46]. Several tissues, also release Prochemerin 
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including liver, spleen, lymph nodes, epithelia, endothelia, adrenal glands, pancreas, 
placenta, lung, skin, platelets etc. 
Various studies showed circulating chemerin was elevated in inflammatory diseases, 
such as erythematosus, rheumatoid arthritis, psoriasis, Crohn’s disease associated 
with markers of inflammation and found to regulate leucocyte recruitment towards 
the site of inflammation. It was also found to play a role as an important adipocyte-
signaling molecule in adipogenesis, angiogenesis, osteo-blastogenesis, myogenesis, 
glucose homeostasis or even proposed a role in inhibiting bacteria growth. Therefore, 
the original notion of chemerin mainly as a leukocyte chemoattractant has been 
substantially challenged and broadened over the years. Taken together, chemerin 
emerges as a protein of interest for a number of disciplines, including immunology, 
dermatology, metabolism and development. 
1.2.1 Regulation 
The expression, secretion and processing of chemerin is tightly coordinated through 
a number of mechanisms which is essential for establishing chemerin levels, 
localization and, ultimately, activity. The regulation occurs both transcriptionally and 
post translationally. 
1.2.1.1 Transriptional regulation of chemerin activity 
Chemerin is regulated a by variety of inflammatory and metabolic mediators on a 
transcriptional level. They can be broadly classified as  
i) Nuclear receptors agonists (retinoids, vitamin D, glucocorticoids),  
ii) Metabolic factors (e.g. fatty acids, insulin, glucose) and  
iii) Immunomodulatory mediators (e.g. cytokines of acute or chronic 
inflammation and LPS) 
Regulation of chemerin expression by nuclear receptors agonists 
Tazarotene (a synthetic retinoid acid analog), an agonist of the nuclear retinoic acid 
receptors β and γ (RARβ/γ), was the first identified factor to induce chemerin 
expression in psoriatic lesions and skin rafts (Table 1.2) [43].  
Agonists of the steroid/thyroid/vitamin D3 nuclear receptor family, such as 1,25 
dihydroxyvitamin D3 (1,25D3/calcitriol) and synthetic glucocorticoid-derivative 
dexamethasone (DEX) markedly induced TIG2 mRNA in the stromal cell line ST2 
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during osteoclast differentiation [47]. Significant chemerin expression was also 
observed when 1,25D3 administered to primary cultures of fibroblasts from healthy 
or psoriatic skin. [48]. 
Another member of the nuclear hormone receptor superfamily, peroxisome 
proliferator-activated receptor γ (PPARγ) was reported to elevate chemerin 
expression in BMSCs (Bone marrow mesenchymal stem cells) treated with 
Rosiglitazone (PPARγ agonist) [49]. Silencing of PPARγ in these cells resulted into 
almost loss of rosiglitazone-induced TIG2 expression [50]. Troglitazone, another 
agonist of PPARγ, increased TIG2 mRNA in 3T3-L1 cells during their 
differentiation [51].  
In human and mouse liver hepatocytes, a synthetic ligand of nuclear receptor 
farnesoid X (FXR), GW4064 induced chemerin expression dose dependently, 
suggesting a correlation between chemerin and FXR (Table 1.2) [52]. 
Regulation of chemerin expression by metabolic factors 
Chemerin is also under regulation of metabolic factors, such as free fatty acids (FFA) 
and insulin. FFA in 3T3-L1 cells up regulates chemerin synthesis during their 
differentiation into adipocytes. Plasma chemerin levels were significantly increased 
following insulin infusion in healthy individuals and adipocyte tissue explants. 
Metformin, an antidiabetic drug suppressed chemerin synthesis and secretion in 
adipocyte tissue explants in PCOS patients, suggesting a communication between 
chemerin and insulin/glucose (Table 1.2) [53]. 
Regulation of chemerin expression by cytokines 
TNFα (Tumor necrosis factor alpha) is a cell signaling protein (cytokine) that is 
found to have an ambiguous role in controlling chemerin expression. In vitro study 
showed that TNFα significantly increased TIG2 mRNA expression in 3T3-L1 
adipocytes, but suppressed TIG2 transcription and chemerin secretion in renal 
proximal tubular epithelial cells [54].  
Interleukin 1 beta (IL-1β), a member of the interleukin 1 family of cytokines, was 
reported to increase TIG2 mRNA and chemerin protein concentrations significantly 
in 3T3-L1 adipocytes derived conditioned medium and immortalized brown 
adipocyte tissue (BAT)-derived cells (Table 1.2)  [55]. Interferon gamma (IFNγ), the 
only member of the type II class of interferons was reported to enhance robust 
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chemerin expression by fibroblast like synoviocytes [56]. An elevated serum level of 
IFNγ has been detected in diseases postulated to be involved with chemerin such as 
psoriasis or rheumatoid arthritis [57]. 
The mechanism or pathways involved in the regulations of chemerin 
expression/secretion by IL-1β or IFNγ have yet to be defined. 
Table 1.2 : Regulation of chemerin expression by inflammatory and metabolic 
factors (Adapted from Zabel et al., 2014). 
Cell type Nuclear receptors/ 
nuclear receptor 
ligands 
Metabolic 
factors 
Immunomodulat
ory mediators 
Epithelial cells    
Human skin keratinocytes Tazarotene (RARβ/γ), 
SR 11217/ SR 11237 
(RXR)-, 1,25D3- 
  
Fetal human intestinal cells ATRA (RARβ)  TNFα 
Human intestinal enterocyte-
like Caco2 cells 
  TNFα 
Human renal tubular 
epithelial cells 
1,25D3-  TNFα, IFNγ, 
IL1β, TGFβ 
    
Fibroblasts    
Human skin fibroblasts 1,25D3-  IFNγ, IFNα, 
TNFα, CXCL8, 
TGFβ 
Human synoviocytes   TNFα, IFNγ, 
IL1β, IL6, TGFβ 
    
Chondrocytes    
T/C-28a2, human 
immortalized chondrocytes 
IL1β Adiponectin, 
leptin 
LPS 
ATDC-5 mouse 
chondrogenic cell line 
DEX Adiponectin, 
leptin 
IL1β, LPS 
Osteoclasts-suppurting 
mouse stromal ST2 cell line 
1,25D3, DEX   
    
Adipocytes    
Human adipocytes/ 
adipocyte tissue explants 
PPARγ (troglitazone) 
(mRNA, protein), 
gonadal and adrenal 
steroids 
Adiponectin, 
insulin, 
metformin, 
FFA 
(SREBP2) 
TNFα 
Mouse adipogenic cell line 
3T3-L1 
PPARγ (troglitazone)  TNFα, IL1β 
Bone marrow mouse 
mesenchymal stem cell 
PPARγ (rosiglitazone)   
    
hepatocytes    
Human hepatoma HepG2 
cell line 
FXR (GW4064)   
Mouse hepatocytes FXR (GW4064)  TNFα 
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1.2.1.2 Posttranslational regulation/ proteolytic processing 
Total circulating chemerin in a healthy population is 90-200 ng mL-1 in both serum 
and plasma. Females and older adults have higher total circulating chemerin than 
males and younger adults reportedly, although not evident by all studies [58]. 
Human chemerin is initially synthesized as a 163 amino acid precursor, 
preprochemerin (chemerin 1–163) along with an N-terminal signal sequence (20 aa), 
which is cleaved off before secretion into an inactive 18-kDa precursor, prochemerin 
(chemerin 20–163 or Chem-163) [59]. When this cleavage occurs, either co- or post-
translationally during translocation to the endoplasmic reticulum, is still not clear.  
The majority of chemerin in the circulation is functionally inactive prochemerin, 
bearing a cystatin-like fold-containing domain and a labile C-terminus that can be 
cleaved at multiple distinct sites by a variety of extracellular proteases. This releases 
a terminal inhibitory peptide resulting into a number of bioactive isoforms with 
varying length and biological activity [60].  
Several isoforms have been isolated from several human biological specimens (Table 
1.4). Chem-157 lacks six amino acids from C-terminus is the most biologically 
active isoform (approximately 100-fold higher than prochemerin. Chem-156 (not yet 
reported in human biological fluids) is slightly less active than Chem-157, Chem-155 
and -158 showed low activity, and Chem-152 and -154 are relatively inactive (Table 
1.3) [59]. 
Extracellular proteases that process chemerin include; serine proteases of the 
coagulation, fibrinolytic and inflammatory cascades such as neutrophil elastase and 
cathepsin G, mast cell tryptase, plasma-derived factor XIIa, VIIa and plasmin, as 
well as host cysteine protease such as cathepsins K and L (Table 1.3) [60] 
Among those proteases, some can process prochemerin at more than one site (e.g. 
elastase, tryptase [61], while some can process an already precessed isoform. For 
example, carboxypeptidases B and N process relatively low active chemerin isoforms 
into more active forms [62]. Chemerin can also be controlled by proteases from 
human pathogens other than host ones. Staphopain B, a potent cysteine protease 
derived from Staphylococcus aureus activates the chem-157 variant [46]. 
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Table 1.3 : A: In the human chemerin primary amino acid sequence (NCBI 
Reference Sequence: NP_002880.1) the following regions are shown: functionally-
evaluated chemerin peptides displaying antibacterial activity (green) or chemotactic 
activity (blue), inhibitory C-terminal region (red). B: Processing of prochemerin by 
different proteases. (Adapted from Zabel et al., 2014 and Rourke et al., 2012). 
(A) human Chemerin primary amino acid sequence 
1.      
MRRLLIPLALWLGAVGVGVAELTEAQRRGLQVALEEFHKHPPVQWAFQETSVESAVDTPF 
61.    PAGIFVRLEFKLQQTSCRKRDWKKPECKVRPNGRKRKCLACIKLGSEDKVLGRLVHCPIE 
121.  TQVLREAEEHQETQCLRVQRAGEDPHSF149YFPGQF154AFS157KALPRS163 
 
(B) Processing of prochemerin by different proteses 
Protease Cleaves Generates C-terminal sequence Resulting 
activity 
Prochemerin 
(chem21-163) 
  ... PGQFAFSKALPRS Inactive 
Carboxypeptidase 
N or B 
Chem-158 Chem-157 ... PGQFAFS Converts high 
to highest 
Cathepsin G Chem-163 Chem-156 ... PGQFAF High 
Cathepsin K, L Chem-163 Chem-157 ... PGQFAFS Highest 
Human leucocyte 
elastase 
Chem-163 Chem-157 
Chem-155 
Chem-152 
... PGQFAFS 
... PGQFA 
... PG 
Highest 
Low 
Inactive 
Mast cell chymase Chem-156 
Chem-157 
Chem-154 ... PGQF Converts high/ 
highest to 
inactive 
Mast cell tryptase Chem-163 Chem-158 
Chem-155 
... PGQFAFSK 
... PGQFA 
Low 
Low 
Plasmin Chem-163 Chem-158 ... PGQFAFSK Low 
Proteinase 3 Chem-163 Chem-155 ... PGQFA Low 
Staphopain B Chem-163 Chem-157 ... PGQFAFS Highest 
Table 1.4 : Biological sources of chemerin isoforms ((Adapted from Rourke et al., 
2012). 
Biological source Identified isoforms 
Ascites (20) Chem-157 
Cerebrospinal fluid (23,25) Chem-158 
Hemofiltrate (22) Chem-154 
Plasma (24,25) Chem-155, -157, -158, -163 
Synovial fluid (25) Chem-158 
Extracellular proteases are also engaged in inactivating or degrading the attractant, 
therefore limiting the extent of chemerin activity. Tissue-recruited neutrophils 
secrete chemerin-activating elastase and cathepsin G, but also release proteinase 3 
that cleaves chem-163 to chemotactically inactive chem-155 [63]. Mast cell chymase 
converts bioactive chemerin into relatively inactive Chem-155 [64]. This Chem-155 
might act as a weak antagonist in the presence of highly active chemerin isoforms 
[65].
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In chemerin isoform specific ELISAs, it was found that majority of chemerin in 
inflammatory milieus is proteolytically processed, pointing towards extensive 
proteolytic processing of chemerin during inflammation in vivo [66]. 
1.2.2 Receptors and signalling 
There are three known heptahelical receptors for chemerin: CMKLR1, GPR1, and 
CCRL2. These receptors bind to chemerin with similar low nanomolar affinities but 
with substantially different functional outcomes. 
CMKLR1, or ChemR23 or Chemerin receptor, is the seven-pass transmembrane G 
protein-coupled receptor located on chromosome 12q24.1. It shares homology with 
some chemoattractant receptors, such as somatostatin receptors, anaphylatoxin C3a 
and C5a receptors, and formyl peptide receptors [67]. 
CMKLR1 is highly expressed in leukocyte populations, particularly immature 
dendritic cells (DCs), resident macrophages and cytotoxic natural killer (NK) cells. It 
has also been located in adipose tissue, bone, lung, brain, heart, placenta [68,69], 
recently in human endothelial cells (ECs) and cultured human venous smooth muscle 
cells [66]. 
CMKLR1 activation by chemerin triggers several biological responses. These 
include; intracellular calcium mobilization, β-arrestin2 association and receptor 
internalization, up-regulation of the phosphatidylinositol 3-kinase/Akt signalling 
pathway, down-regulation of NF-kB and inhibition of cAMP and MAPK ERK1/2-
mediated signalling [6].  
GPR1, G protein-coupled receptor 1, a member of the G protein-coupled 
receptor family of transmembrane receptors, is expressed in adipose tissue, central 
nervous system (CNS), skeletal muscle and in a limited manner in leukocytes [32]. 
Chemerin binding to GPR1 triggers β-arrestin2 association and receptor 
internalization. It may involve in regulating local chemerin level as well by 
functioning as a chemerin-binding ‘interceptor’ that binds, internalizes, and degrades 
chemerin [70]. 
CCRL2, CC-motif chemokine receptor-like 2, is an atypical chemerin receptor 
expressed by mast cells, activated macrophages and dendritic cells, and vascular 
endothelial cells. In vivo studies showed CCRL2 regulation in circulating chemerin 
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levels and its proteolytic processing during systemic inflammation. It mediates 
chemerin localization, presents it to nearby cells and thereby contributing to 
CMKLR1 and potentially GPR1-mediated processes [71]. 
1.2.3 Chemerin initiates an inflammatory response in inflammation and diseases 
Polymorphonuclear leukocytes or PMNs (Neutrophils, eosinophils, and basophils) 
are the first cells recruited early at the sites of active tissue injury or inflammation, 
which release a set of proteases that generate bioactive chemerin. Blood coagulation 
and human pathogen-derived proteases may also contribute to the increased 
chemerin activity. After activation, chemerin mediates the recruitment of CMKLR1-
expressing Antigen-Presenting Cells (APC) such as macrophages, immature DCs and 
several other types of immune cells at inflammatory sites; thereby triggering an early 
immune response (Figure 1.6) [72]. 
 
Figure 1.6 : Chemerin driven development of inflammatory response (Adapted from 
Francesco & luca et al., 2014). 
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Serum chemerin levels are significantly elevated in patients with chronic 
inflammation, such as Crohn’s disease, ulcerative colitis, chronic kidney disease, 
chronic pancreatitis, pre-eclampsia, polycystic ovary syndrome and liver disease with 
higher inflammatory markers such as C-reactive protein (CRP), IL-6 and TNFa, as 
well as the pro-inflammatory adipokines leptin and resistin [73]. 
Upregulated chemerin levels are often observed in diseased tissues in both mice and 
humans, such as psoriasis, cancer, arthritis, lupus and multiple sclerosis. Human 
studies on rheumatoid arthritis, osteoarthritis (OA) and psoriatic arthritis showed 
twofold increase of chemerin in localized synovial fluid but little or no change in 
serum level. This point out an idea that elevated chemerin level is often associated 
with inflamed tissue that may or may not correspond to a similar change in 
circulating chemerin levels [74].  
Furthermore, the ratio of cleaved to total chemerin is dramatically increased and is 
often associated with unique isoform profiles that differ considerably from the 
distribution of isoforms in circulation [75]. 
1.2.4 Chemerin/Chemerin receptor signaling in inflammation and diseases 
Numerous in vitro and animal studies have demonstrated the involvement of 
chemerin in chemotaxis of CMKLR1-expressing leukocytes such as human 
macrophages, immature DCs and natural killer (NK) cells to sites of localized 
inflammation, tissue damage or bleeding. These leukocyte populations evaluate local 
conditions and initiate an appropriate immune response. Thus, based on the stimuli 
confronted by recruited CMKLR1+ cells and importantly, the tissues and disease 
being investigated, chemerin may aggravate or ameliorate the local inflammatory 
response. 
The role of chemerin and CMKLR1 signaling has been investigated in a handful of 
inflammatory disease models, usually with the use of conventional CMKLR1 
deficient mice or exogenous administration of chemerin to recruit cells to a particular 
anatomic location. 
The recruitment and retention of leukocytes at sites of infiltration by chemerin was 
supported by a study on murine macrophages where chemerin facilitates the adhesion 
of murine macrophages to extracellular matrix proteins and endothelial cells [76]. 
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Chemerin signaling has been found to be required for advancing optimal tissue 
swelling and leukocyte infiltration in various mouse inflammation models such as 
IgE-mediated anaphylaxis and lipopolysaccharide (LPS)-induced pulmonary 
inflammation [71].  
Consisting with this, CMKLR1 knockout mice exhibited reduced CNS inflammation 
in EAE (experimental autoimmune encephalomyelitis), a model of autoimmune 
demyelinating disease [77]. This finding is also supported by a study that used 
COPD (cigarette smoke- induced chronic obstructive pulmonary disease) model. 
CMKLR1 KO mice developed less severe pulmonary inflammation associated with a 
reduction in PMN, DCs and CD4+ T cells infiltration into the airways [78]. All these 
clinical and experimental data suggest a pro-inflammatory role of 
chemerin/CMKLR1 signaling. 
However, several inflammation models experimented on animals such as peritoneal 
inflammation, LPS-induced lung injury and acute viral pneumonia exhibit 
exacerbated inflammation and decreased leukocyte infiltration when endogenous 
chemerin activity is inhibited or CMKLR1 expression is lost. In vitro study showed 
marked inhibition of TNFa, IL-1b, IL-6, IL-12 and RANTES like pro-inflammatory 
mediators by chemerin through classically activated murine macrophages [79]. In a 
transplantable melanoma model, tumor-expressed chemerin inhibited in vivo tumor 
growth by NK cell depletion or CMKLR1 deficiency [80]. 
Additionally, CMKLR1 KO mice developed more severe pulmonary inflammation 
associated with an increased leukocyte infiltration into the lung, high viral burden 
and delayed viral clearance in PVM model (an infectious model of viral pneumonia) 
study [81], suggesting an anti-inflammatory role of the chemerin/CMKLR1 
signaling. 
Therefore, both pro- and anti-inflammatory role for chemerin has been suggested by 
various studies. It may be due to different isoforms of chemerin that could potentially 
play contrasting roles in various stages of inflammation, on different population in a 
particular condition. 
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1.2.5 Chemerin/Chemerin receptor signaling in macrophages 
As macrophages in both human and mouse predominantly expresses ChemR23, they 
most likely play a central role in chemerin-mediated development of inflammatory 
diseases. 
After activation, as stated before, chemerin facilitates the chemotaxis and adhesion of 
macrophages to extracellular matrix proteins and endothelial cells through increased 
adhesion to fibronectin and VCAM-1 and promotion of integrins clustering (VLA-5 
and VLA-4) in a ChemR23-dependent manner [76] 
Although ChemR23 expression is predominantly observed both in human and mouse 
macrophages, the regulation and eventual function of ChemR23 can be varied in 
these two species. A previous study on mouse macrophages showed that 
inflammatory stimuli, such as TLR ligands (LPS, CpG) and inflammatory cytokines 
like IFN-g and TNF-α down regulated Chem23 expression whereas anti-
inflammatory cytokines like TGF-β caused upregulation, suggesting the role of 
ChemR23 in naive and anti-inflammatory macrophages only [76, 82]. 
However, LPS, TNF-a and IFN-g stimulation increased ChemR23 expression in 
human monocytes and macrophages [83]. This concept is further supported by some 
studies on mouse inflammation models that found ChemR23-dependent anti- 
inflammatory and protective effects of chemerin, whereas in humans, chemerin was 
found to be directly associated with chronic and systemic inflammation [84]. 
Different isoforms of Chemerin can also function differently in modulating 
macrophages. It was found that active chemerin-156 induced proinflammatory 
cytokines expression on macrophages whereas alternative digestion products of 
chemerin increased anti-inflammatory cytokines such as IL-10. [85]. 
The differential expression pattern of ChemR23 on stimulated macrophages and the 
possible opposite effect of chemerin on inflammation between mouse and human 
may indicate that the role of ChemR23 signaling differs between the two species. 
Chemerin/ ChemR23 signaling also plays a potential role in the polarization of 
macrophages. In an Inflammatory Bowel Disease (IBD) study on DSS (Dextran 
sulfate sodium) induced colitis model, exogenously administered chemerin is shown 
to significantly decrease colonic expression of all the M2 associated genes, Arg-1, 
Ym1, FIZZ1 and IL-10. This is further supported by an in vitro study done by the 
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same group, proposing the involvement of chemerin in the resolution of IBD by 
suppressing M2 macrophage polarization [86]. 
Interestingly another study showed functional CMKLR1 expression on human M1 
macrophages but not on M2 macrophages in vitro. This classically activated human 
M1 macrophages are prone to chemotaxis by chemerin and produce increased IL10 
expression. This finding provides another aspect to the study performed by lin et al 
group and would be interesting to assess the effect of chemerin on M1/M2 
polarization in other models as well [87]. 
Chemerin has been found to play a role in the recruitment of macrophages to the 
developing fetal intestine, indicating a much more complex and vast relation with 
macrophages not only limited to inflammation. Intestinal macrophages are the first 
phagocytic cells of the innate immune system to combat luminal bacteria in fetal 
intestine and have a unique adaptive mechanism to prevent unnecessary 
inflammation in the gut mucosa. These macrophages do not undergo clonal 
expansion and continuous recruitment from blood monocytes is necessary for 
development and maintenance of gut macrophages. While chemerin contributes to 
the shaping of mucosal immunity by continuous recruitment of macrophages in the 
developing fetal intestine, the expression of chemerin is low in the mature intestine 
[88]. 
1.3 Macrophages 
Macrophages, also known as ‘big eaters’ or ‘phagocytes’, were first discovered and 
presented by Ilya Metchnikoff which had led him earn the Nobel Prize for Medicine 
in 1905 [89]. The name came from two Greek words, ‘makros’ meaning ‘large’ and 
‘phagein’ meaning ‘to eat’. Macrophages are heterogeneous and dynamic immune 
cells that are present in almost all tissues in human under different names, forms and 
different functions.  They engulfs and digests cellular debris, foreign substances, 
pathogens, cancer cells, and anything else that does not have the types of proteins 
specific of healthy body cells on its surface through the process phagocytosis, hence 
the name macrophages. Macrophages are the first line defense of innate immunity 
system against pathogens and play a critical role in initiating the adaptive immune 
response via antigen processing and presenting to other leucocytes [90]. They take 
part in both generation and resolution of inflammation, tissue repair and wound 
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healing [91]. Although macrophages are very effective in initiating immune response 
and phagocytosis, some microbes develop strategies to escape and interfere with 
macrophage activation and modulate host responses [92]. 
1.3.1 Monocyte / macrophage development 
Monocytes are generated by bone marrow from myeloid hematopoietic progenitor 
cells (Figure 1.7). After generation, they circulate into the peripheral blood stream, 
and within three days or so, typically migrate into different tissues. Half of the 
population migrates into the spleen, which serves as a reservoir for immature mono-
cytes [93] and the rests mature into different types of macrophages and/or dendritic 
cells in different tissues when exposed to local growth factors, cytokines, pathogens 
or pathogen related compounds [94]. The entire process is known as “mononuclear 
phagocyte system”. The variety of undifferentiated monocytes in the circulation 
could affect their polarization status in various tissues [95]. Monocytes are primarily 
involved in eliminating invading organisms (bacteria, virus, fungi, and protozoans) 
although could potentially bring about negative effects on the pathogenesis of 
inflammatory and degenerative diseases [96]. 
 
Figure 1.7 : The mononuclear phagocyte system (adapted from Lawrance & Natoli, 
2011) (solid lines represent common pathway of development and dashed lines 
represent alternative pathway of development). 
23 
Macrophages can be divided according to their anatomical location with specific 
names; such as osteoclasts (bone), alveolar macrophages (lung), histiocytes 
(interstitial connective tissue), Kupffer cells (liver) etc (Figure 1.8) [95]. These 
tissue- resident specific macrophages patrol for potential pathogens, engulf foreign 
substances and recruit additional macrophages from circulation during an infection 
or injury with other specified functions. 
Such as, macrophages present in the gut work as groups to maintain tolerance to the 
gut flora and the food ingested. Macrophages present in the spleen (marginal zone 
macrophages) inhibit innate and adaptive immune response against apoptotic cells 
[97], macrophages of lymph nodes (subcapsular sinus) eliminate viruses and activate 
antiviral humoral immune responses [98,99]. Nonetheless, macrophages present in 
the immune-privileged sites, such as the brain (microglia), eye and testis focus 
mainly on tissue remodeling and homeostasis. 
 
Figure 1.8 : Different tissue macrophages (adapted from Murray & Wynn, 2011). 
However, not all tissue resident macrophages are differentiated from monocytes. For 
example, Langerhans cells in the skin and microglial cells in the CNS proliferate 
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locally. Recent studies indicate development of these cells from M-CFU in the yolk 
sac of the developing embryo [100]. 
Macrophages are distinguished from dendritic cells (DCs) or other mononuclear cells 
by differential expression of specific surface makers such as CD11a, CD11b/CD18, 
CD11c, CD14, and CD68. 
1.3.2 Pathogen recognition of macrophages via Toll-like receptors 
The toll-like receptors (TLRs) on macrophages recognize PAMPs derived from 
microbes and danger signals; initiate inflammatory responses; activate microbial 
killing and clearance mechanisms [101]. They have also been described as 
‘necessary’ or ‘required’ for an adaptive immune response. There are 13 known 
paralogous of TLRs present; among which 10 is present in humans and 12 in mice 
(Figure 1.9). 
TLR4 present on macrophages identifies LPS from cell walls of Gram-negative 
bacteria and initiate two separate signaling pathways regulated by two separate 
adaptor proteins, MyD88 or Toll/IL-1R domain–containing adapter inducing IFN-b 
(TRIF) [102]. TLR4 stimulation activates inflammatory cytokines production such as 
tumor necrosis factor TNF-a, IL-1 and IL-6. Flagellin of H. pylori were found to be 
recognized by TLR5 [79]. 
 
Figure 1.9 : Toll like receptors and their ligands (adapted from styliani et al., 2016). 
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However, LPS and flagellin of H. felis were identified by TLR2, and it’s signaling 
depends on MyD88 adapter protein, unlike typical LPS and flagellin whose 
recognition is not dependent on TLR4 or 5 as (Figure 1.5).  
Study conducted by Sayi et al. (2011) [33] showed that H. felis activates B 
lymphocytes through TLR2 with up-regulated CD40, MHC-II and other co-
stimulatory molecules and production of IL-10, IL-6, IgM and IgG2b. (Figure 1.8). 
TLR2 identify helicobacter mosty due to the uncommon lipid composition of the 
bacterial envelope with high concentration of lysophospholipids and cholesteryl 
glucosides [103] (Figure 1.5).  
1.3.3 Macrophage polarization and plasticity 
Macrophages can be polarize into different phenotypes under the influence of 
different stimuli. During tumor progression, phenotypical change of macrophages 
from classically (M1) to alternatively activated (M2) has been observed [104] 
whereas in obesity, it changes to M2 from M1 [105]. These findings suggest the 
notion that polarization of macrophages alters according to stimuli given and the 
local microenvironment as well, enabling them to form the local inflammatory status 
to adjust to external stimuli [91]. However, These two subtypes do not exist as 
distinct populations excluding each other out, rather they often coexist. The balance 
of activatory and inhibitory activities and the tissue environment often determine the 
resulting mixed phenotype. 
1.3.3.1 Classically activated macrophages (M1) 
The M1 macrophage phenotype is typically described by elevated production of pro-
inflammatory cytokines, marked resistance to pathogens, strong microbicidal 
characteristics, marked production of reactive nitrogen and oxygen intermediates, 
and promotion of Th1 or TH17 immune responses (Figure 1.12). Stimulation with 
LPS, IFN-gamma and granulocyte-macrophage colony stimulating factor (GM-CSF) 
assist in polarizing M1 macrophages with secretion of high amounts of pro-
inflammatory cytokines such as IL-1-beta, tumor necrosis factor (TNF), IL-12, IL-18 
and IL-23 (Figure 1.12) [106,107]. These macrophages express high levels of major 
histocompatibility complex class I and II (MHC I & II), the CD68 marker, and co-
stimulatory molecules CD80 and CD86, various pro-inflammatory chemokines and 
secrete complement factors for complement-mediated phagocytosis (Table 1.5) 
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[108]. Increased expression of the intracellular protein suppressor of cytokine 
signaling 3 (SOCS3) has also been observed, as well as nitric oxide synthase 
(NOS2 or iNOS) to produce NO from L-arginine [109] (Figure 1.10).   
Different stimuli could potentiate different responses on M1 type macrophages. For 
instance, Stimulation of macrophages with IFN-γ results in higher levels of IL-12 
and IL-23 with low levels of IL-10 [95,110]. While secreted IL-12 facilitates Th1 
response with improved phagocytosis [111], IL-23 promotes the development and 
expansion of Th17 cells with high levels of IL-17, causing inflammatory 
autoimmune pathologies [112,113]. 
Various transcription factors and post-transcriptional regulators form a network that 
is involved in M1 polarization. Upon activation by IFNs and toll-like receptor 
(TLR), The IRF/STAT pathways initiate M1 polarization via STAT1 [104]. On the 
other hand,The LPS/TLR4 pathway activates STAT1-alpha/beta in a MyD88 
independent fashion to polarize M1. In the presence of LPS, Bruton’s tyrosine 
Kinase (Btk) has been implicated in macrophage polarization to M1. Induction of 
NO production by P2Y(2)R, a G protein coupled receptor via NOS2 and SOCS3 via 
NF-κB/PI-3 kinase pathways promotes M1 markers (Figure 1.10) [114]. 
M1 type macrophages can be identified by F4/80, CD11b, and CD11c+ surface 
marker expressions in a recent obesity study (Table 1.5) [115,116]. They secure 
resistance to intracellular bacteria and control the acute phase of infection. Listeria 
monocytogenes infection in immunocompromised patients and pregnant women, M1 
type macrophages were shown activated and mediated intracellular killing of bacteria 
is in vitro and in vivo [117]. M1 macrophages have also play a role in infections 
caused by L. monocytogenes [118], Salmonella typhi, Salmonella typhimurium [119] 
and Mycobacterium tuberculosis [120].  
M1 macrophages are responsible for sustained inflammation in various diseases 
including gastroenteritis, urinary tract infections, neonatal meningitis, and sepsis, and 
can therefore be detrimental to health [121]. 
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Figure 1.10 : Signaling molecules involved in M1 polarization. 
1.3.3.2 Alternatively activated, M2 type macrophages 
 Alternatively activated macrophages are mainly described by their contribution to 
parasite control, reduction of inflammation, immune regulation, tissue remodeling, 
tumor progression and efficient phagocytic activity (figure 1.12) [122]. M2 
macrophage is activated by various stimuli including fungal cells, immune 
complexes, helminth infections, complement components, apoptotic cells, 
macrophage colony stimulating factor (MCSF), IL-4, IL-13, IL-10 and TGF-beta. 
They secrete high amounts of IL-10 and low levels of IL-12 and IL23 [110, 123]. M2 
macrophage embraces a functionally diverse group of populations, which can be 
further subdivided into M2a, M2b, M2c and M2d according to distinct gene 
expression profiles [108]. The M2a macrophage is stimulated by IL-4, IL-13 or 
fungal and helminth infections. IL-1 receptor ligands, immune complexes and LPS 
induce M2b subtype. M2c is activated by IL-10, TGF-beta and glucocorticoids. The 
fourth type, M2d is stimulated by IL-6 and adenosine. M2d macrophages are similar 
to ovarian TAMs bot phenotypically and functionally but are different from M2a-c 
(Table 1.5) [124, 125]. 
 
28 
Table 1.5 : Classically activated (M1) and alternatively activated (M2) subset 
phenotypes (Adapted from Rőszer T 2015 and Duluc D et al. 2007). 
 M1 M2a M2b M2c M2d 
Stimulation/activatio
n 
IFN-gamma 
LPS 
GM-CSF 
IL-4 
IL-13 
Fungal and 
Helminth 
infection 
ICs 
IL-1R 
 
IL-10 
TGF-
beta 
GCs 
IL-6 
LIF 
Adenosi
ne 
Marker expression 
CD68 
CD86 
CD80 
MHC II 
IL-1R 
TLR2 
TLR4 
iNOS 
SOCS3 
CD163 
MHC II 
SR 
MMR/CD206 
CD200R 
TGM2 
DecoyR 
IL-1R II 
Mouse only: 
Ym1/2 
Fizz1 
Arg-1 
CD86 
MHC II 
CD163 
TLR1 
TLR8 
VEGF 
Cytokine secretion 
TNF 
IL-1beta 
IL-6 
IL-12 
IL-23 
IL-10 
TGF-beta 
IL-1ra 
IL-1 
IL-6 
IL-10 
TNF-
alpha 
IL-10 
TGF-
beta 
IL-10 
IL-12 
TNF-
alpha 
TGF-
beta 
 
Chemokine secretion 
CCL10 
CCL17 
CCL22 
CCL24I 
CCL1 CCR2I 
CCL5 
CXCL10 
CXCL16 
CCL11 
CCL5 
CCL8 
CCL9 
CCL2 
CCL3 
CCL4 
M2 macrophage embraces a functionally diverse group of populations, which can be 
further subdivided into M2a, M2b, M2c and M2d according to distinct gene 
expression profiles [108]. The M2a macrophage is stimulated by IL-4, IL-13 or 
fungal and helminth infections. IL-1 receptor ligands, immune complexes and LPS 
induce M2b subtype. M2c is activated by IL-10, TGF-beta and glucocorticoids. The 
fourth type, M2d is stimulated by IL-6 and adenosine. M2d macrophages are similar 
to ovarian TAMs bot phenotypically and functionally but are different from M2a-c 
(Table 1.5) [124, 125]. 
The signalling molecule involved in macrophage polarization is STAT 6 (Figure 
1.11) [126]. IL-4/IL-13 receptor signaling activates STAT6 mediated upregulation of 
Arginase 1, a specific trademark of M2 polarization. Krüppel-like factor 4 (KLF-4) 
coordinates with STAT6 to induce M2 genes such as Arg-1, Mrc1, 
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Fizz1 and PPARγ, and inhibit M1 genes such as TNF-alpha, Cox-2, 
CCL5 and NOS2 [127]. The NF-κB  
 
Figure 1.11 : Signaling molecules involved in M2 polarization. 
p50 subunit (as homodimers) also plays an important role in M2 polarization in 
vitro and in vivo [128] as well the nuclear receptor, peroxisome proliferator-activated 
receptor γ (PPARγ) [129]. The hypoxia inducible factors HIF-2α controls arginase 1 
expression and the M2 state [130]. IRF4 negatively regulates M2 polarization in a 
MyD88 independent fashion [131] and BMP-7 positively regulates M2 
polarization in vitro through SMAD-PI3K-Akt-mTOR pathway (Figure 1.11) [132]. 
M2 macrophages have distinct chemokine and chemokine receptor profiles, secreting 
CCL17, CCL22 and CCL24 (Table 1.5). Recent in vitro studies showed 
that, macrophages can completely repolarize between themselves, from M2 to M1 
and vice versa, depending on the chemokine environment [133].  
1.3.3.3 Tumor associated macrophages (TAMs) 
Studies in mice models exhibited that macrophages aid in surviving malignant tumor 
cells to survive and growing in distant sites, potentially involve in metastasis which 
is one of the major causes of patient’s death. Macrophages are one of the major 
populations of infiltrating leukocytes associated with solid tumors [95]. Circulating 
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monocytes can be recruited into the tumor microenvironment through secretion of 
chemotactic molecules by the tumor itself and mature into TAMs [134]. Mice model 
study suggested such tumor infiltrating monocyte pool to be primarily of Ly-
6C+CX3CR1low, and TAM monocyte precursors to be Ly-6Chigh cells exclusively 
[135]. 
 
Figure 1.12 : Inducers and selected functional properties of classically (M1) and 
alternatively (M2) activated macrophage populations (adapted from Evita et al., 
2015). 
TAMs actually stands for a population of various macrophage subsets, primarily of 
M2-like phenotype [136] although studies have shown the presence of both M1 and 
M2 subsets [137,138]. TAMs are known to promote tumor progression and are 
associated with poor prognosis. They facilitate angiogenesis, lymphogenesis, stroma 
remodeling and immune suppression and promote tumor invasion and metastasis 
[139] via secretion of the enzymes plasmin, uPA, matrix metalloproteinases (MMPs) 
and cathepsin B (Figure 1.13) [140,141]. 
The transcriptional profile of TAMs is distinct from M1 and M2 macrophages [142]. 
They are phenotypically categorized as CCL2hiCCL5hiIL-10hi, express MGL-1, 
Dectin-1, CD68, CD206, VEGF-A, NOS2, CD81, MHC II and scavenger receptor A 
[143-44]. In addition, they exhibit enhanced IRF-3/STAT-1 activation and defective 
NF-κB signaling [142]. 
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Figure 1.13 : TAM functions in tumor progression (adapted from Hao et al., 2012). 
Infiltration with TAM has been assoaciated with poor prognosis observed in Hodgkin 
disease, glioma, cholangiocarcinoma, and breast carcinoma [145-46]. For the 
identification of TAMs, CD163 surface marker generally is used [147-48].       
1.3.4 Immune response against Helicobacter pylori 
H. pylori- induced inflammation is stimulated by different bacterial factors that 
stimulate epithelial cells, macrophages, and DCs activation, also pre-dominant Th1 
response. Actually, colonization of H. pylori can be prevented by immunizing the 
host with bacterial components such as urease [149] indicating activation of the 
adaptive response. However, urease is a major activator of macrophages, stimulating 
cytokine and NO generation [150]. Therefore, distinguishing between purely an 
innate or adaptive response is difficult, and the recognition that cells such as B cells  
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can respond to H. pylori directly or via the interaction of activated T cells illustrates 
the complexity of the host immune response [151]. 
Chronic infection of H. pylori named as “chronic superficial gastritis” [152] in which 
T cell, B cell, macrophage, neutrophil, mast cell, and dendritic cell (DCs) infiltration 
is seen [153-54]. CD4+ T cells present more abundantly than CD8+ T cells. 
CD4+/CD25hi/ FOXP3+ natural regulatory T cells (Tregs) also seen in higher 
numbers in the gastric mucosa of H. pylori- infected individuals, hence, they seemed 
to have an important role in the regulation of inflammatory response [155]. 
Therefore, H. pylori specific- chronic gastric mucosal inflammatory response occurs 
in a combination of cellular immune response and an ongoing stimulation of an 
innate immune response. 
1.3.4.1 Innate immune response against Helicobacter pylori 
Epithelial cells 
TLRs present on Gastric epithelial cells can identify pathogen-associated molecular 
patterns (PAMPs). When bacteria penetrate into the gastric epithelial barrier, the 
alternative complement pathway is activated, and macrophages and neutrophils are 
recruited to infected area. However, H. pylori do not invade gastric tissue, it localize 
within the gastric mucus layer. Therefore, contact between H. pylori and phagocytic 
cells do not take place unless gastric epithelial barrier disrupts [156]. 
High levels of pro-inflammatory cytokines including IFN-g, TNF-a, IL-1b, IL-6, IL-
7, IL-8, IL-18 had been observed in the stomachs of patients infected with H. pylori 
compared to uninfected humans as well as IL-10, which may limit the inflammatory 
response [157]. Polymorphisms, which reduce the production of anti-inflammatory 
cytokines such as IL-10, increase the risk of gastric cancer. Also, polymorphisms of 
IL-1b, TNF-a, and IL-10 combined, increase the risk of cancer 27- fold over 
baseline [158]. 
In 2004 Graham et al. conducted a study with 20 human volunteers who were 
infected with 104 to 1010 CFU of H. pylori to observe course of infection. More than 
50% of subjects displayed symptoms including dyspepsia, headaches, anorexia, 
abdominal pain, belching, and halitosis, during the second week following infection. 
Lymphocyte and monocyte infiltration was examined in gastric biopsies with 
significant increase of IL-1b, IL-8, and IL-6 cytokine expression in the gastric 
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antrum [159]. The numbers of gastric CD4+ and CD8+ T cells were higher following 
four weeks of infection. These observations indicated development of gastric 
inflammation a short while after H. pylori infection. The upper gastro-intestinal 
symptoms of acute infection are resulted by initial colonization of the bacteria in the 
stomach. If H. pylori infection persists, it becomes chronic and unless cleared, with 
the help of the immune response, may lead to gastric carcinoma.  
Dendritic cells (DCs) 
Dendritic cells are the professional antigen-presenting cells (APCs) and act as a 
bridge between innate and adaptive immune responses (Figure 1.14) [160-61]. These 
cells can penetrate epithelial monolayers and engulf bacteria directly [162-63]. Upon 
recognition of PAMPs by the surface TLRs, dendritic cells activate T cells either in a 
Th1 or Th2/ regulatory T-cell (Treg) response through exhibiting bacterial products 
to T cells [164]. Ex vivo stimulation of human peripheral blood mononuclear cell- 
derived DCs with H. pylori led to higher production of IL-12 and IL-10 [165-66]. 
Moreover, activated DCs co-cultured with naïve T cells induced TNF-a, IFN-g, and 
IL-2 secretion, initiating Th1 response [167].  
Ex vivo stimulation of mouse bone marrow- derived DCs with H. pylori led to higher 
production of pro- inflammatory cytokines such as IL-1a, IL-1b, and IL-6 b with 
improved phagocytosis [168]. However, an Ex vivo study observed skewing of 
Th17/Treg balance towards Tregs by activated DCs, thereby contributing to bacterial 
immune evasion [169] and leading to chronic inflammation and cancer risk. 
Neutrophils 
Neutrophils are the first-responders of immune response that migrate to the site of 
inflammation and clear invading pathogen through phagocytosis and releasing 
enzymes that kill microorganisms. During the onset of H. pylori infection, 
neutrophils migrate into the gastric mucosa and initiate inflammation (Figure 1.14), 
although bacteria can persist even when neutrophils are present in the localized 
environment by manipulating phagocytosis and oxidative reactions. H. pylori secrete 
neutrophil-activating protein (HP-NAP), a virulance factor that promotes neutrophil 
recruitment and induces production of reactive oxygen radicals [170-71]. Recognized 
by TLR2, HP-NAP upregulates IL-12, IL-23, and TNF-α [172], therefore promoting 
Th1 cells, increased production of IFN-γ, TNF-α and cytolytic activity. 
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Figure 1.14 : Innate and adaptive immune response stimulated by Helicobacter 
pylori (adapted from Peek et al., 2010). 
Macrophages 
Monocytes, macrophages and dendritic cells present in the lamina propria of the 
gastric mucosa play important roles in antigen presentation [153,164]. During the 
onset of H. pylori infection, macrophages and DCs activate adaptive immune 
response through production of IL-12 [173], initiating Th1 response and IFN-γ 
production. The virulence factor HP-NAP mediated IL-12 and IL-23 secretion by 
neutrophils and monocytes contributes to Th1 polarization as well (Figure 1.14) 
[172]. Macrophages also amplify the inflammatory response by production of 
cytokines such as IL-1b, TNF-α, and IL-6 [174]. 
H. pylori stimulates the expression of inducible NO synthetase (iNOS) in gastric 
mucosal epithelial cells, vascular endothelial cells or infiltrated inflammatory 
immune cells. Increased iNOS mediates NO production using L-arginine as a 
substrate in these cells, macrophages being the chief source among them all [175]. 
Although in vitro experiments observed that NO produced by macrophages could 
potentially kill H. pylori [176] but not in human stomach, hence the chronic 
inflammation persists in the gastric mucosa. The bacterial LPS also suppresses NO 
production by stimulating polyamine-mediated apoptosis of macrophages [177] and 
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iNOS expression by inducing arginase and ornithine decarboxylase (ODC) (Figure 
1.13) [178].   
The gastric biopsy specimens taken from H. pylori positive individuals showed 
CD163+ alternatively activated (M2 type) macrophages. Human monocytes also 
secreted IL-1b, IL-6, IL-10, and IL-12p40 upon infection (partially secreted as IL-
23) but not IL-12p70. Upregulation CD14 and CD32 and downregulation of CD11b 
and HLA-DR are observed. Human M2 macrophages exhibited CD14 and CD206 
upregulation with increased IL-10 but less pro-inflammatory cytokines than M1 
macrophages [179]. 
B7-H1(CD80) and B7-H2 (CD86) expressions were markedly increased on T cells, 
macrophages, and dendritic cells after activation [180] upon H. pylori infection.  In 
vitro studies showed H. pylori stimulation increased expression of co-stimulatory 
molecules and MHC-II in human monocytes [181] but failed to up-regulate on 
gastric mucosa. This could be due to the prevalence of Tregs and IL-10 in the H. 
pylori infected gastric mucosa that inhibits the up-regulation of co-stimulatory 
molecules and MHC-II on macrophages [182]. 
In mice, vaccination against H. pylori polarizes gastric macrophages to M1. Also, in 
human atrophic gastritis where the mixed M1/M2 subsets present  is replaced by an 
M1 phenotype, creating a tumor-promoting inflammation. Therefore, shifting 
macrophage polarization from M1 to M2 could be a therapeutic target in chronic H. 
pylori infection. 
Although H. pylori can be internalized into phagosomes by macrophages, they still 
can escape from phagocytosis by fusing phagosomes into “megasomes” that contain 
large numbers of live bacteria. The CAG+ strains of H. pylori secretes VacA toxin 
that prevents the fusion of phagosomes to lysosomes necessary for bacterial killing. 
This disruption of phagosome maturation is lost when cells are infected with isogenic 
vacA− mutant strains [183]. 
1.3.4.2 Humoral immune response against Helicobacter pylori 
H. pylori-specific serum IgM antibodies present in the infected ones turns on 
humoral Immune response concomitantly with the adaptive response, usually 
observed after 4-weeks of post-infection approximately [184]. Serum IgA and IgG 
antibodies were directed toward many different H. pylori antigens [185-86]. These 
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H. pylori-specific IgA or IgM antibodies secreted from activated plasma were 
directed toward many different H. pylori antigens in the gastric mucosa [185]. This is 
further supported by the evidence found in gastric juice where secretory IgA 
antibodies were present, indicating the onset of local secretory IgA response in the 
stomach [187]. 
1.3.4.3 Adaptive immune response against Helicobacter pylori 
T cells 
IFN-g, the key defining cytokine of Th1 response was seen to be highly expressed 
from gastric T cells of H. pylori-infected individual [188-89]. IFN-g could potentially 
reduce bacterial colonization but augment the severity of H. pylori- induced gastric 
inflammation, supported by the study performed on IFN-g-/- knockout mice [190-91]. 
IFN-g also activates macrophages indirectly to secrete more pro-inflammatory 
cytokines and reduces expression of anti-inflammatory cytokines (e.g TGF-b) 
(Figure 1.14), together of which may increase the severity of gastritis [192]. 
In order to investigate the Th2 response on Helicobacter infection, mice co-infected 
with nematode (Th2 response inducer) and H. felis had sufficiently reduced Th1 
cytokine profile (IFN-g, TNF, and IL-1b), boosted Th2 cytokines expression (IL-4, 
IL-10, and TGF-b) with less gastric inflammatory scores than only H. felis infected 
mice [193]. However, Th2 response may not be required for protection from H. 
pylori infection as seen in the study where IL-4 and IL-5 knockout mice were 
successfully protected after immunization [194]. Another study on MHC class I-/- 
mice model revealed that CD4+ T, but not CD8+ T cells cells are necessary for 
protection against Helicobacter infection [195]. 
Th17 response (IL-17 expression) was observed when mice were immunized with H. 
pylori lysate and when CD4+ T cells isolated from spleens were co-cultured with H. 
pylori-treated DCs or macrophages, with augmented gastric inflammation and 
reduced colonization [196].  
H. pylori infected individuals have increased levels of CD4+ CD25high FOXP3 
expressing Tregs in the gastric and duodenal mucosa [197], depletion of which may 
cause increased gastritis severity, higher cytokine profiles as well as serum IgG1 and 
IgG2c levels and reduced bacterial colonization in a mice model [198]. This study 
suggests that an important role of Treg response to uphold a sense of balance 
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between host and bacterium, allowing H. pylori to survive while at the same time 
preventing the risk of detrimental inflammation. 
B cells 
B-cell-deficient (µ-MT) mice progress to severe gastritis upon H. pylori with 
eventual clearance of infection due to absence of antibodies produced by wild-type 
mice which block the inhibitory IgG receptor (FcgRIIb) on leukocytes and increase 
anti-inflammatory cytokines such as IL-10 [199]. IL-10 is a potent anti-inflammatory 
and immunoregulatory cytokine that reduces H. pylori-induced inflammation, 
supported by a study conducted on Helicobacter-infected IL-10-/- mice that develop 
severe gastritis [200]. Similar results have also been observed in H. pylori-infected 
IL-4-/- mice, suggesting a role of both IL-10 and IL-4 in down-regulating gastric 
inflammation [201-02]. 
In the study of gastric MALT lymphoma, chronic infection of H. pylori was observed 
to protect splenic B cells from apoptosis, indicating development of B-cell 
activation/survival phenotype associated in MALT lymphoma [203].  
In mouse, B cells recognized Helicobacter by TLR2 and produce anti-inflammatory 
IL-10 through activation of myeloid differentiation primary response gene 88 
(MyD88), both in vitro and in vivo. Decreased IL-10 expression had observed in both 
TLR2 or MyD88 knock-out mice (TLR2-/-or  MyD88-/-) w i t h  a c c e l e r a t e d  
g a s t r i c  h i s t o p a t h o l o g y .  IL-10 producing regulatory B cells inhibit strong 
Th1-mediated immune response via suppression and conversion of CD4+ T cells 
into IL-10-producing T regulatory 1 (Tr-1) (Figure 1.14) [33]. Bregs work in 
harmony in order to restore the immune balance in Helicobacter-infection by 
minimizing excessive gastric immunopathology while preventing bacterial 
clearance in the gastric mucosa [33]. This study was significant for demonstrating a 
B cell subset with regulatory function in a bacteria-associated disease model for 
the first time. 
1.4 Purpose of Thesis 
Chemerin has been regarded as one of the major attractants for macrophages 
observed in many disease studies. The effect of Helicobacter pylori (H. pylori) on 
macrophage polarization is somewhat investigated in both human and mice studies as 
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well as the role of chemerin on macrophage polarization. However, no studies have 
yet investigated the effect of chemerin on the polarization status of macrophages in 
H. pylori induced pathogenesis. Therefore, in this study, we investigated the 
expression of chemerin on H. pylori treated gastric epithelial cell lines first to 
observe the role of chemerin and H. pylori on gastric immunity. On the second part, 
we investigated the role of both chemerin and H. pylori on monocytic cell line THP-
1 and observe the differences on its polarization status according to cytokine profiles. 
Expression levels of M1 type specific cytokines (IL-1b and IL-6 ) and M2 type 
specific cytokine (IL-10) were assessed. 
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 MATERIALS AND METHODS  
1.5 Materials 
1.5.1 Bacteria 
Helicobacter pylori Wild type (G27) and its ΔCagA mutant were kindly provided by 
Prof. Dr. Anne Müller from University of Zurich. Bacteria were spreaded on 
Columbia Agar plates supplemented with 1000X and 200X antibiotic cocktails. 
Ingredients of Columbia Agar (BD, U.S.A.) plate, 1000X and 200X antibiotic 
cocktails were given in Table 1 and Table 2, respectively. Solutions and chemicals 
used in the maintenance of Helicobacter pylori are given in Tables 2.1, 2.2 and 2.3. 
 Components of Columbia Agar Plates. 
Component Amount 
Columbia Agar 42,5 g 
Horse Blood 50 ml 
β-cyclodexin 10 ml 
1000X Antibiotic Cocktail 1 ml 
 Components of 1000X Antibiotic Cocktail. 
Content Amount 
Trimethoprim 100 mg 
Amphotericin B 160 mg 
DMSO 20 ml 
 Components of 200X Antibiotic Cocktail. 
Content Amount 
Vancomycin 100 mg 
Cefsulodin 50 mg 
Polymixin B 3.3 mg 
H2O 50 ml 
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1.5.1.1 Antibiotics 
Antibiotics used in Helicobacter pylori Columbia agar plate are listed in Table 2.4. 
 Antibiotics used in Helicobacter pylori culture. 
Content Supplier company 
Trimethoprim HiMedia 
Amphotericin B HiMedia 
Vancomycin HiMedia 
Cefsulodin HiMedia 
Polymixin B HiMedia 
1.5.1.2 Liquid culture 
Ingredients of liquid culture of Helicobacter pylori are shown in Table 2.5 with 
a representative volume of 50 ml. The volume of ingredients may change 
depending on the required volume of components for proper growth of bacteria. 
 Components of Helicobacter pylori liquid culture. 
Content Amount 
Brucella Broth 50 ml 
FBS [10% (v/v)] 5 ml 
Vancomysin (1000X) 5 µl 
1.5.1.3 Freezing Helicobacter pylori 
The medium suitable for freezing Helicobacter pylori for stock purposes is depicted 
in Table 2.6 with its ingredients. Upon preparation the medium can be stored at 4°C. 
 Freezing medium for Helicobacter pylori. 
Component Amount 
Brucella Broth 25 ml 
Glycerol 25 ml 
1.5.2 Cell lines 
KATO III, AGS, MKN 45 and THP-1 cell lines were used for this study. KATO-III 
human gastric adenocarcinoma cell line was kindly provided by Doç.Dr. Rengül 
Çetin Atalay of Bilkent University, Ankara, Turkey. 
1.5.3 Cell culture 
Culture media and solutions used in cell culture studies can be seen in Table 2.7 
and buffers used in cell culture studies are listed in Table 2.8. 
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 Solutions and media used in cell culture studies. 
Solution Supplier Company 
Roswell Park Memorial Institute (RPMI) 
Medium Lonza 
Dulbecco’s Modified Eagle Medium 
(DMEM) Lonza 
Fetal Bovine Serum (FBS) (10%) Lonza 
Penicillin/Streptomycin (1%) Gibco 
Trypan Blue Lonza 
DMSO Fisher-Scientific 
 Buffers and media used in cell culture studies. 
Buffers Content and Amount 
1X PBS 9,55g in 1L ddH2O 
Complete RPMI growth medium RPMI medium with 10% FBS, 1% Penicillin/Streptomycin 
Complete DMEM growth medium DMEM medium with 10% FBS, 1% Penicillin/Streptomycin 
RPMI Freezing medium FBS:RPMI:DMSO (5:4:1 ratio, v/v) 
DMEM Freezing medium FBS:DMEM:DMSO (5:4:1 ratio, v/v) 
Trypsin-EDTA 0.25% (1X) 
Detaching buffer 10 mM EDTA in 1X PBS  
1.5.4 Equipments and supplies 
Laboratory equipment and supplies used in this study are shown in Table 2.9 and 
Table 2.10 with their companies, respectively. 
 Laboratory equipments used in the study. 
Equipment         Company 
Laminar Air Flow Cabinets FASTER BH-EN 2003 
Pipettes 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl 
Socorex and 10 µl, 100 µl, 1000 
µl Biohit 
Electronic Pipette CappAid 
 
 
Centrifuges 
Beckman Coulter Allegra ™ 25 
R 
Centrifuge 
Scanspeed 1730 
R  
Labogene Scanspeed 
mini 
Incubator with CO2 BINDE
R Nanodrop 2000 Thermo Scientific 
Shakers Heidolp Duomax 1030 
Step One Real Time Systems Applied Biosystem 
Sonicator Bandelin Sonopuls 
Vortex Mixer Uzusio VTX-3000L, LMS 
Quick spin LMS 
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Table 2.9 (cont’d): Laboratory equipments used in the study. 
Equipment Company 
Magnetic stirrer WiseStir MSH-20D, Wisd Laboratory 
Equipment 
Light Microscope Olympus CH30 
Hemacytometer Isolab 
Ice Machine Scotsman AF10 
 
Freezers 
Altus ( + 4 
0C) 
Siemens ( -20 
0C) Haier (- 80 
0C) 
Flow Cytometer BD Accuri C6 
Nitrogen Tank Air Liquid 
Microplate Spectrophotometer BIO-RAD Benchmark Plus 
Fluorescent Microscope Zeiss Axiovert A1 Inverted 
Confocal Microscope Leica SP2 
 Laboratory supplies used in the study. 
Supplies Company 
Nitrocellulose membrane (0.2 µm pore 
size) Santa Cruz 
Scale Precisa 
Examination Gloves Beybi 
Tissue culture flasks (25 cm2, 75 cm2) Sarstedt 
Anaerobic Jar Anaerocult 
Erlens Isolab 
Falcons (15 ml, 50 ml) Isolab 
Slides Interlab 
Coverslips Interlab 
Cotton Swap Interlab 
96-well F plate (for for Real time) Nunc 
6-well and 24-well F plate Sarstedt 
Tissue flasks Sarstedt 
Serological pipettes Sarstedt 
Centrifuge tubes Sarstedt 
Eppendorf tubes (0,6ml, 1,5ml, 2ml) Interlab 
Cell strainer (70 µm) BD 
1.5.5 Commercial kits 
Commercial kits used in this study are listed with their supplier companies in the 
table below (Table 2.11). 
 Commercial kits used in this study. 
Kit Supplier Company 
BCA™ Protein Assay Reagent Assay Thermo Scientific 
NucleoSpin RNA Isolation Kit Macherey-Nagel 
High capacity cDNA syntesis Kit, 200 rxns Applied Biosystems 
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Table 2.11 (cont’d) : Commercial kits used in this study. 
Kit Supplier Company 
PCR kit New England Biolabs 
Power SYBR® Green PCR Master Applied Biosystems 
1.5.6 Reagents used in cloning 
Necessary reagents for molecular cloning was kindly provided by Associate 
Professor Doc Asli Kumbasar. 
 Reagents for cloning. 
Reagents Supplier Company 
HindIII-HF and XhoI Restriction 
enzymes New England Biolabs 
CutSmart Buffer New England Biolabs 
Nucleospin Gel and PCR Clean-up, 50 
preps Macherey Nagel 
DNA Ligation Kit Clonetech 
Zyppy Plasmid Miniprep Kit Zymoresearch 
PEI (Polyethylenimine) Sigma-Aldrich 
 Reagents for Luria Broth agar and medium. 
Reagents Amount (For 500 ml) Supplier Company 
Tryptone 5 g Lab M Neogen 
Yeast 2.5 g Lab M Neogen 
Nacl 5 g Merck Millipore 
For medium, Agar no. 2 
(Bacteriological) 
7.5g Lab M Neogen 
Water Upto 500 ml   
1.5.7 General chemicals 
General chemicals used in this study are listed with their supplier companies in Table 
2.14. 
 General chemicals used in this study. 
Chemical Supplier Company 
EDTA Applichem 
Ethanol (absolute) Merck 
NaCl Merck 
Glycerol Merck 
Phosphate-Buffered Saline (PBS) 10X Lonza 
Tween-20 Fisher-Scientific 
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Table 2.14 (cont’d) : General chemicals used in this study. 
Chemical Supplier Company 
Bovine Serum Albumin (BSA) Santa Cruz 
DMSO Fisher Scientific 
β-Mercaptoethanol Sigma-Aldrich 
Columbia Agar BD 
Brucella Broth BD 
CampyGen 2.5L Oxoid 
Lipopolysaccharide (LPS) Sigma-Aldrich 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich 
Fixation Buffer (4%) Biolegend 
Permeabilization Buffer (10X) Biolegend 
Isopropanol Sigma-Aldrich 
HCl Sigma-Aldrich 
NaOH Sigma-Aldrich 
Xylol Sigma-Aldrich 
Sodium Citrate Sigma-Aldrich 
Triton-X 100 Sigma-Aldrich 
Donkey Serum Sigma-Aldrich 
1.5.8 Primers 
Primers used in this study are given in table 2.15.  
 Primers used in the study and their sequences. 
Primer 
Name Sequence (5’-3’) Spec. Tm 
Exp. 
Size 
Chemerin Fw 
Chemerin Rv 
GGAATATTTGTGAGGCTGGAAT h 60°C 139 bp CAGGCATTTCCGTTTCCTC 
Chemerin Fw 
(for cloning) 
Chemerin Rv 
(for cloning) 
TATAAGCTTATGCGACGGCTGCTGATCCCT 
h 68°C 105 bp 
ATACTCGAGTTAGCTGCGGGGCAGGGCCTT 
Chem Rec 
Fw 
Chem Rec Rv 
GAGAGATGGGCTTCCCTCTGGTC 
h 65.3°C 103 bp TGAATGAACTGCTTTCTGGGCA 
IL-1β Fw 
IL-1β Rv 
GGCTTATTACAGTGGCAAT h 57.1°C 124 bp GAAGCCCTTGCTGTAGTG 
IL-6 Fw 
IL-6 Rv 
CCTGAGAAAGGAGACATGTAA h 54°C 103 bp AGTCTCCTCATTGAATCCA 
IL-10 Fw 
IL-10 Rv 
AAGCCTGACCACGCTTTCTA h 60°C 120 bp GCTCCCTGGTTTCTCTTCCT 
18s rRNA Fw 
18s rRNA Rv 
GGCCCTGTAATTGGAATGAGTC m/h 60°C 146 bp CCAAGATCCAACTACGAGCTT 
Oligo dT TTTTTTTTTTTTTTTTTTTT - - - 
45 
1.5.9 Antibodies 
Antibodies used in this study are given in table 2.16. 
 Antibodies used in this study. 
Antibody Supplier Company Application 
Rat anti-mouse/human 
CD11b-biotin Biolegend FACS 
Rat anti-mouse/human 
CD14-PE Biolegend FACS 
Rat anti-mouse/human 
CD68-biotin Biolegend FACS 
Anti-mouse Alexa Fluor 
488 Biolegend FACS 
streptavidin-PE Biolegend FACS 
streptavidin-APC Biolegend FACS 
   
Goat anti-human 
Chemerin  RnD WB 
Rabbit anti-human 
GAPDH 
Cell 
Signaling WB 
 Anti-Goat IgG-HRP Cell Signaling WB 
Anti-Rabbit IgG-HRP Cell Signaling WB 
Donkey anti-Goat 
AF488 Invitrogen 
FACS, IF, 
IHC 
1.6 Methods 
1.6.1 Maintenance of Helicobacter pylori 
Helicobacter pylori was seeded on a Columbia blood agar containing appropriate 
antibiotics and incubated at 37°C under microaerophilic conditions in an anaerobic 
jar for 3-4 days. Microaerophilic conditions in anaerobic jar were maintained by 
utilization of CampyGen packs. For preparation of Columbia agars, 42,5 g Columbia 
agar was dissolved in 1000 ml water. Liquid was autoclaved. The bottle was put in 
560C water bath for an hour. 50 ml horse blood was added to the agar. 10 ml b-
cyclodexin and 1 ml of 1000X antibiotic cocktail (see table 2.2) was added for H. 
pylori growth. After 3-4 days, the grown bacteria were checked under light 
microscope for their viability and mobility, and transferred into liquid Brucella Broth 
containing 10.000 X Vancomycin (final concentration: 1X) with necessary dilutions 
for optimal growth. For preparation of Brucella Broth medium, 28 g of brucella broth 
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powder was resuspended in 1L of sterile distilled water (ddH2O). Following 
resuspension, the liquid medium was autoclaved at 121°C for 15 min for 
sterilization. 
1.6.2 Sonication of Helicobacter pylori 
Sonication procedure was started with 120-200 ml liquid culture of Helicobacter 
strains. Before sonication Helicobacter pylori (10 µl)’s mobility was checked under 
light microscope. 120- 200 ml liquid culture of Helicobacter pylori was aliqouted to 
15 ml falcons. Falcons were centrifuged at 3000 rpm for 10 minutes, and supernatant 
was discarded. 10 ml PBS was used to wash bacteria. 15 ml falcon was centrifuged at 
3000 rpm for 7 minutes, and supernatant was discarded. 3.5 ml PBS was added on 
pellet and mixed. Tube was taken to sonication with ice. Sonication was performed 
as 30 second pulse on, 50 second pulse off for 6 minutes 30 seconds at 50 watts (MS 
72 probe of the sonicator was used). They were aliquoted to 1.5 ml eppendorfs at 500 
µl for each. They were centrifuged at 4 °C, 5000 rcf (3000 rpm) for 10 minutes. 
Supernatant was taken to new eppendorf tubes and labeled. Sonicate concentration 
was measured with BCA assay. 
1.6.3 Protein bicinchoninic acid (BCA) assay 
The determination of protein concentration was performed using Thermo Scientific’s 
Protein BCA Assay. The Bradford dye was diluted with distilled water at 1:4 ratios. 
Bovine Serum Albumin (BSA) Standard Set was chosen for microassay. 1X BCA 
working reagent was prepared from Solution B and Solution A as 1:50 ratio, 
respectively and was warmed to ambient temperature. 200 µl of working reagent was 
distributed into each assayed well of a 96-well plate, and all the samples were 
duplicated to confirm linear range of standards and to get more accurate results. 10 
µL of diluted BSA standards in duplicates were put into working reagent-containing 
wells with the concentrations of 0,025; 0,125; 0,25; 0,5; 1; 1,5; 2 mg/mL, 
respectively. Dilution scheme for BSA standards are given in Table 2.15. 10 µL of 
protein samples (diluted of undiluted) with unknown concentrations were put into 
working reagent-containing wells, and microplate was incubated at 37°C for at least 
30 minutes. After 30-minute-long incubation, absorbances were measured at 562 nm 
on microplate reader. 
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 Dilutions of BCA assay standards. 
Vial Volume of diluents ddH2O (µl) 
Volume & source of 
BSA 
(µL) 
Final BSA 
Concentration 
(µg/ml) 
A 0 300 of stock 2,000 
B 125 375 of stock 1,500 
C 325 325 of stock 1,000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0=Blank 
1.6.4 KATO III, AGS, MKN 45, THP-1 and HEK293T cell culture 
Three gastric cancer cell lines KATOIII, AGS and MKN45 were used in this study. 
All cell lines except HEK293T were cultured in RPMI 1640 with 10% fetal bovine 
serum and 1% penicillin/streptomycin under a humidified atmosphere containing 5% 
CO2 at 37 ◦ C. HEK293T cells were cultured in DMEM under the same condition 
mentioned above. Confluent cells were passed routinely at a split ratio recommended 
by the distributor after trypsin/EDTA digestion for attached/mixed population. All 
cell lines are adherent in nature except THP-1 cells. cells were frozen in freezing 
medium containing complete DMEM/RPMI with %50 FBS and %10 DMSO. 
1.6.4.1 Cell thawing 
9 ml required RPMI/DMEM medium was added to a 15 ml falcon tube. Frozen cells 
were thawed with the warmth of hand briefly. The cells were dissolved with 
completely in medium and centrifuged at 1000 rpm for 5 min to remove DMSO 
(which is toxic for cells) from cells. The supernatant was discarded carefully 
following centrifugation. ~5 ml fresh medium for T25 flask or ~12 ml fresh medium 
for T75 flask was added to the pellet and the pellet was dissolved in the medium. The 
viability of cells was checked under the microscope before placing the flask to the 
incubator (37°C + 5% CO2). 
1.6.4.2 Cell passage 
Cell density was determined on light microscope. When reached to almost 80% 
confluence, suspension cells were put on a 15 ml falcon tube and centrifuged at 1000 
rpm for 5 minutes. The supernatant was discarded and the pellet was dissolved in 4 
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ml culture medium and 1 ml cells (2×106 cells) were taken in a new flask with a fresh 
culture medium. For adherent cells, the flask was washed once with 12 ml 1X PBS 
and 1500 µl of trypsin-EDTA 10X was added to flask. The flask was incubated at 
370 C for 4 minutes. Then the flask was taken and mechanic force was applied to 
flask. 3-4 ml of culture medium were added to inhibit the effect of trypsin. 1ml cells 
(2x10
6 
cells) were taken in a new flask with a fresh culture medium 
1.6.4.3 Cell freezing 
The medium was discarded from the flask. PBS was added to flask to wash cells and 
then discarded. 1,5 ml trypsin was added to T75 flask and incubate for 4 min. at 
37°C. Attachment of cells were controlled under the microscope. Approximately 9 
ml medium was added to T75 flask to inactivate trypsin and centrifuged at 1000 rpm 
for 5 min.  The supernatant was discarded and 1 ml freezing medium was added 
(supplemented with growth media and 10% DMSO) to the pellet and dissolve the 
pellet in the freezing medium. Frozen cells were stored at -80°C. 
1.6.4.4 Cell counting 
Growth medium was removed from the flask and washed once with 1X PBS. 1.5 ml 
of Trypsin treatment from 10X stock was added to flask to breaks down the 
disulphate bounds and waited 4 min. at 370C incubator. Then 4 ml growth medium 
was added to the flask for inhibition of Trypsin solution.10 µl suspension was taken 
into 1.5 µl eppendorf tube and 1µl of trypan blue was added to check the viability of 
cells. Then 10 µl of cell suspension was put onto the hem cytometer and the cells 
were counted. 
1.6.4.5 Treatment of KATO III, AGS and MKN 45 cell lines with Helicobacter  
pylori sonicate 
When cells were fully-grown in culture media, cells were detached, counted and 
seeded into 6 well plates as 4x105 cells/well. The cells were rested for 24 hours 
before treatment started so that they can gain stability and attach to the surface of the 
well. After 24 hours of resting, each well was treated with 10 ug sonicates of H. 
pylori strain, G27 which is the wild type and G27-ΔCagA strain along with the 
control group. After designated period of incubation, in this case 6,24,48 and 72 
hours cells, were harvested. 
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1.6.4.6 Cell harvesting 
After designated time frame of incubation cells were harvested. At first 
medium/supernatants were collected from each group. After removing the 
supernatant, each well was washed with PBS 1X (0.5-1 ml/well) and then PBS was 
discarded. After washing, 400 µl of Trypsin-EDTA was added to wells for the 
detachment of cells and plates were incubated at 37ºC for 2-3 minutes. The plates 
were then checked under the microscope to confirm detachment of the cells and 
adding same amount of fresh medium neutralized trypsin. After that, the cells were 
collected and pelleted by centrifugation at 3000 x rpm for 8 min. Cell pellets were 
stored in -800C for further experiments. 
1.6.5 RNA isolation 
To determine relative expression levels, bone marrow derived and peritoneal 
macrophages pellets were used to isolate their RNA. 350 µl of RA1 lysis buffer and 
3,5 µl b-mercaptoethanol was added to cell pellets and vortex vigorously. Samples 
were taken to nucleospin filter (violet ring) tubes and centrifuged at 11,000 x g for 1 
minute. Nucleospin filter (violet ring) was discarded and 350 µl of 70% of ethanol 
was added to lysate and mixed by pipetting up and down (5 times). For each 
preparation, one nucleospin RNA column (light blue ring) was placed into a 
collection tube and lysates were pipetted up and down 2-3 times more and loaded to 
the column. Columns were centrifuged at 11,000 x g for 30 seconds. 350 µl of MBD 
(membrane desalting buffer) was added and centrifuged at 11,000 x g for 1 minute to 
dry the membrane. Then, DNase reaction mixture was prepared. For each isolation, 
in a sterile 1,5ml microcentrifuge tube, 10 µl reconstituted rDNase (reconstituted by 
manifacturer’s guides) was added to 90 µl reaction buffer for rDNase, and mixed by 
flicking by the tube. Then, 95 µl DNase reaction mixture was applied directly onto 
the center of the silica membrane of the column. Column was incubated at room 
temperature for 15 minutes. After incubation, 200 µl of RAW2 buffer was added and 
centrifuged at 11,000 x g for 30 seconds to inactivate the rDNase. Then, 600 µl of 
RA3 buffer was added to column and centrifuged at 11,000 x g for 30 seconds. 
Lastly, columns were placed onto new collection tubes, 250 µl of RA3 buffer was 
added onto the column and centrifuged at 11,000 x g for 2 minutes to dry the 
membrane. Finally, columns were settled into new eppendorf tubes. To elute the 
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RNA, 35 µl of RNAse-free water was added on columns and columns were 
centrifuged at 11,000 x g for 1 minute. Flow through was kept as isolated RNA. To 
get more concentrated RNA, flow through was put onto the center of the column 
once and centrifuged again at 11,000 x g for 1 minute. RNA concentrations were 
measured with NanoDrop. 
1.6.6 cDNA synthesis 
Synthesis of cDNA was performed according to manufacturer’s instructions. 
Amounts used in synthesis reaction are given in Table 2.18. Synthesis conditions are 
given in Table 2.19. 
 cDNA synthesis reaction components. 
Component Amount 
RNA (1µg) Depends on concentration 
ddH2O 15.075 µl – amount of RNA 
10X RT Buffer 2 µl 
Oligo dT (10µM) 1 µl 
Ribolack Rnase inhibitor 0,125 µl 
Reverse transcriptase enzyme 1 µl 
25X dNTP mix 0,8 µl 
 cDNA synthesis reaction conditions. 
Temperature  Time  
25°C 10 min 
37°C 120 min 
85°C 5 min 
4°C ∞ 
1.6.7 Conventional PCR  
In order to check the cDNA, 18S rRNA primers were used for the conventional PCR. 
Apart from that, the mRNA expression of chemerin, chemerin receptor, IL-1β, IL-6 
and IL-10 was measured. Required PCR reagents are shown in below Table 2.20 and 
Conventional PCR conditions are indicated in Table 2.21. 
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 Reagents for PCR. 
Component  Amount  
10X Buffer 2.5 ul 
10 mM dNTP 0.5 ul 
10 uM Forward primer 0.5 µl 
10 uM Reverse primer 0.5 µl 
Taq Polymerase 0,125 µl 
ddH2O 19.875 µl 
Template 1 µl 
 Conventional PCR reaction conditions. 
 Temperature  Time   
Initial 
Denaturation 94°C  30 sec 1 cycle 
Denaturation 94°C 30 sec 
35 cycle Annealing 54-68°C 45 sec 
Extension 72°C 45 sec 
Final 
Extension 72°C 5 min 1 cycle 
Hold 4°C ∞  
 
1.6.8 Agarose gel electrophoresis 
2% agarose gel is sufficient for the observation of our expected PCR products. The 
agarose gel contains 2 g agarose in 100 ml 1X TAE. The gel solution was boiled in 
the microwave until the agarose was dissolved. After the cooling, the solution was 
poured in to the gel cassette. Marker was loaded as 2.5 µl always in the first well of 
the gel to evaluate the length of the PCR products. 7.5 µl PCR products were mixed 
with 1.5 µl 6X loading dye. Loading dye was used to facilitate the observation. 1 ul 
Tibo Gold was used for every samples along with the marker for detection. Gel was 
run at 90V for 15 minutes and then 110 V for another 15 minutes. The bands were 
observed with UV trans-illuminator by the help of UV PhotoMW software. 
1.6.9 Real time PCR 
Relative expression levels of 18s RNA, chemerin and IL-10 were analyzed with 
Real-time PCR. Amounts used in reaction are given in Table 2.22. PCR conditions 
performed are given in Table 2.23. 
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 Components of real time PCR. 
Component  Amount  
Power Sybr Master Mix (2X) 5 µl 
Forward Primer (10 µM) 0,5 µl 
Reverse Primer (10 µM) 0,5 µl 
PCR Grade water 1,5 µl 
 Real time PCR reaction conditions. 
Temperature  Time  
95°C 5 min 
95°C 30 sec 
Depending on primer sets 1 min (45 cycle) 
72°C 1 min 
72°C 5 min 
4°C ∞ 
 
1.6.10 Protein isolation 
For protein isolation, pellets were resuspended in Whole Cell Extract Buffer (WCE) 
containing freshly added 0.1 M PMSF (final conc.: 0.5 mM), 100X HALT Protease 
Inhibitor Cocktail (final conc.: 1X) and 10X Roche Phosphatase Inhibitor Cocktail 
(final conc.: 1X). Samples were incubated on ice for 30 min. Then they were 
centrifuged at 14000 rpm for 10 min. Supernatants were aliquoted as total protein 
samples and stored at -80°C. Protein concentrations were determined by Protein 
BCA Assay. 
1.6.11  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
blotting 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis is a technique 
widely used to separate proteins according to electrophoretic mobility. The proteins 
are separated in gel according to their size. In this study, 5% stacking gel and 10 % 
separating gel were used. Prepared gels were poured between SDS-glasses and left 
for polymerization. After the polymerization, samples were mixed 5X Laemmli 
Buffer and boiled at 100°C for 5 minutes. The gels were placed into the tank and 
were run in running buffer at 90V-150V for approximately 2 h.  
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In order to detect the specific proteins Western Blot technique is used in this study. 
After SDS-PAGE, proteins were transferred from gel to the nitrocellulose membrane 
using Wet Transfer blotting (at 160V for 1h at 4°C). Transferred proteins were 
stained with Ponceau S. After visualizing the proteins, membrane was blocked at 4°C 
overnight in blocking solution (TBS/T containing 5% non-fat dry milk) to prevent 
non-specific binding. Then its incubated with 1:1000-1:2000 diluted primary 
antibodies (in TBS/T containing 5% BSA) at 4°C overnight with gentle shaking. The 
day after, membrane was washed with TBS-T buffer 3 times for 10 minutes in the 
shaker. 1:3000 diluted secondary antibody which was conjugated with HRP enzyme 
prepared again in blocking solution and then membrane was incubated with 
secondary antibody solution for 1-2 hour at 4°C in the shaker. After washing steps of 
membrane 3 times with TBS/T, the HRP substrate 20X LumiGLO ® Reagent (Cell 
Signaling) was diluted in to 1X with distilled sterile water (ddH2O). This substrate is 
required for the visualization of the proteins. The membrane was exposed to X-ray 
film and then developed in Kodak Medical X-ray Processor according to 
manufacturer’s instruction. For the detection of other proteins in the same membrane, 
membrane can wash with TBS/T and can be incubated in other primary antibody. 
1.6.12 Molecular cloning of hChemerin 
Molecular cloning refers to the process by which recombinant DNA molecules are 
produced and transformed into a host organism, where they are replicated. A 
molecular cloning reaction is usually comprised of two components: 1) The DNA 
fragment of interest to be replicated  and 2) A vector/plasmid backbone that contains 
all the components for replication in the host. Steps in molecular cloning of 
Chemerin are as followed. 
1.6.12.1 cDNA synthesis  
Intact RNA of high purity is essential for generating cDNA for cloning applications. 
So for the optimum results, High purity sample RNA was converted to cDNA 
according to the cDNA synthesis mentioned before. 
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1.6.12.2 Conventional PCR  
Conventional PCR was performed for amplification of Chemerin using prepared 
cDNA and primers designed for cloning purposes. The sequence of primers was 
given to primer sections. The reagents and PCR set up was given before. 
1.6.12.3 Vector and insert restriction digest 
For the purpose of cloning, pcDNA3.1 (+) vector was used with restriction sites 
HindIII (911) and XhoI (985). Vector was digested with the mentioned restriction 
enzymes to prepare circular DNA. The insert was digested with the same restriction 
enzymes. The reagents used in this step are followed. 
Briefly, vector and insert was incubated with all the reagents for 60 minutes at 370C 
as required. At the end of insert restriction digest, enzymes need to be deactivated so 
they don't interfere with ligation. In most cases it could be done by heat deactivation. 
The gel purification kit can also serve as an enzyme removal kit. Amounts used in 
reaction are given in Table 2.24. 
 Reagents for vector and insert restriction digest. 
Vector restriction digest Insert restriction digest 
Reagents 50 ul Final conc. Reagents 50 ul Final conc. 
10X Cutsmart 
buffer 5 ul 1X 
10X Cutsmart 
buffer 5 ul 1X 
Vector DNA 5 ul Upto 2 ug cDNA insert 5 ul Upto 5 ug 
Restriction 
enzyme HindIII 
0.5 ul (5 
units) 0.05 unit 
Restriction 
enzyme 
HindIII 
1 ul (10 
units) 0.1 unit 
Restriction 
enzyme XhoI 
0.5 ul (5 
units) 0.05 unit 
Restriction 
enzyme XhoI 
1 ul (10 
units) 0.1 unit 
Nuclease free water Upto 50 ul Nuclease free water Upto 50 ul 
1.6.12.4 Gel purification 
Gel purification allows us to separate vector DNA from uncut fraction, clean PCR 
fragment from unspecific PCR products, primers and uncut fragments, and also 
serves as a quality control for the molecular weight of vector and insert. Briefly, both 
digested vector and insert were electrophoresed using 1% agarose gel prepared by 
the mentioned way. The uncut vector and insert were electrophoresed as well to 
distinguish cut fragments and ensure digestion was done successfully. Then the 
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desired DNA fragments were cut from the gel and purified by Nucleospin Gel and 
PCR Clean-up, 50 preps (Macherey Nagel). NanoDrop measured the amount of 
purified DNA.  
1.6.12.5 Ligation 
During the ligation step the linerized vector and the insert is mixed together and a 
DNA ligase is added. The ligase will fuse their ends forming a circular plasmid. 
Ligation was performed using Clonetech DNA Ligation Kit, version 1 (50 reactions). 
The target backbone was 5428 bp long and the insert was 510 bp (both linerized and 
gel purified). According to the protocols 150 ng backbone vector should be ligated 
with 3-fold excess of insert but bp length should also be considered. 
So regarding length, 
3 fold insert= (510 bp/ 5428 bp) x 150 ng =14.09 ng 
All the components were incubated for 5-10 minutes. A sample of vector with no 
insert has also been ligated to use as a control. Reagents and amounts used in 
reaction are given in Table 2.25. 
 Reagents used for Ligation. 
Reagents Final volume 20 ul 
Ligation buffer 10 ul 
Target backbone 150 ng 
Insert 14.09 ng 
T4 DNA Ligase 1 ul 
Nuclease free water To 20 ul 
1.6.12.6 Transformation 
During this step ligated plasmid is added to chemically competent E.coli cells, and 
expose the cell suspension to a heat shock. The heat shock will introduce the DNA 
inside the cells. At first, the chemically competent E. coli cells were thawed on ice 
for 15 min and ligation mix was added to the competent cells by tapping gently on 
the tube and incubated on ice for 30 minutes. The cells were then subjected to heat 
shock at at 420C for 60 seconds in water bath and placed them again on ice for 5 
minutes. After that 4X (approx. 280 ul) volume of LB medium containing antibiotics 
was added and incubated for 45 min at 370C on a shaker to develop antibiotic 
resistance. Then the cells were centrifuged at 13000 rpm for 1 min, supernatant was 
discarded and pellet was resuspended in the remaining LB medium (200 ul). The 
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approximate volume of LB medium containing cells was transferred to LB plates 
with the help of a spreader in front of a gas burner. The plates were incubated in the 
lid up position for 30 minutes at 370C to dry the liquid on the plate surface and 
flipped them upside down and waited for 24 hours for bacterial growth. After 24 
hours, single colonies were picked from the plate, resuspended in LB medium and 
incubated for 24-48 hours at 370C on shaker and then proceed to the plasmid 
purification step (miniprep). 
1.6.12.7 Plasmid miniprep 
Briefly, The bacterial culture grown on LB medium was centrifuged to maximum 
speed for 30s, supernatant was discarded and the pellet was resuspended in 600 ul of 
water. Then,100 ul 7x lysis buffer was added to each 600 ul and mix by inverting the 
tube by 4-6 times. 350 ul of cold neutralization buffer was added, mixed thoroughly 
and centrifuged to 11,000-16,000 g for 2-4 minutes. The supernatant was collected 
and transferred to zymospin column on a new collection tube and centrifuged for 15 
seconds. Flow through was discarded and 200 ul of Endo-wash buffer was added to 
the column and centrifuged for 30 seconds followed by 400 ul of zappy wash buffer 
and centrifuged for 1 minute. After that the column was transferred to a clean 1.5 ml 
microcentrifuge tube then 30 µl of elution Buffer was added directly to the column 
matrix and let stand for one minute at room temperature followed by centrifuge for 
30 seconds to elute the plasmid DNA. 
1.6.12.8 Transfection 
Hek293T cell line was transfected with plasmid DNA using PEI (Polyethylenimine). 
Briefly Hek293T cell line was cultured in DMEM supplemented with 10% FBS and 
1% penicillin/streptomycin. The cells were split one day before transfection in 
DMEM/10% FBS medium and seeded in a 6 well plate. On the day of transfection, 
3ug of plasmid DNA was diluted in serum free DMEM and 9 ug of PEI was added to 
the diluted DNA solution as a 3:1 ratio of PEI (ug):total DNA (ug). The mixture was 
immediately mixed by vortexing and incubated for 15 minutes at room temperature. 
The DNA/PEI mixture was added to cells and transfected cells were harvested at 48 
hours post-transfection.  
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1.6.13 Immunohistochemistry 
Immunohistochemistry was performed on formalin fixed paraffin embedded human 
gastric tissue samples. Briefly, the frozen slides were incubated for 1 hour at 600C on 
water bath. After that, samples were deparaffinized by washing 3 times in xylene for 
10 minutes followed by washing 2 times for 10 minutes in 100%, 80% and finally 
70% ethanol consequently. Finally samples were rinsed in water thoroughly for 10 
minutes. Antigen retrieval was achieved by immersing the slides in sodium citrate 
solution and boiled for 1 minute with maximum heat and then reduced to 20% for 3 
minute. The slides were cooled at room temperature followed by washing in 1x PBS 
for 10 minutes. Afterwards, slides were incubated with 0.2% Triton X-100 solution 
for 15 minutes followed by subsequent washing with 1x PBS 3 times for 10 minutes. 
Non-specific binding was prevented by incubated slides in a blocking solution 
(contains 10% donkey serum and 3% BSA in 1x PBS) for 1 hour at RT. Slides were 
again washed with PBS 3 times and incubated with human anti-chemerin antibody 
(1:100 dilution) and Pan-cytokeratin (10 ul/sample) overnight. After overnight 
incubation, slides were thoroughly washed with PBS 3 times and then incubated in 
anti-goat AF488 for 1 hour. Slides were rinsed 3 times with PBS, dried and mounting 
medium containing DAPI was added and covered with coverslips. 
1.6.14 Macrophage polarization performed on THP-1 cell line 
Thp-1 cells were cultured according to the protocol mentioned before. When cells are 
fully grown 3x105 were seeded into 12 well plates one day before treatment. Next 
day, cells were differentiated into macrophages by stimulation with 20 nM PMA 
(phorbol 12-myristate 13-acetate) for 48 hrs. A group without PMA treatment was 
also kept as control.  Differentiation into macrophages was determined by increased 
cell attachment to the flasks and by changes in cell morphology: mainly larger cell 
size, number of pseudopodia highly increased. After 48 hours of stimulation, 
medium was discarded, cells were washed with PBS 1X and cultured for another 24 
hours in fresh medium without PMA to induce further efficient differentiation. After 
that Cells were stimulated for 24 hours with different stimulants: LPS (100ng/mL) 
recombinant IL-4 (20 ng/mL) and chemerin (50ng/mL) along with or without H. 
pylori sonicates (G27 wild type and G27-DCagA, 10 ug/ml). After 24 hours of 
incubation cells were harvested and preceded to other experiments. 
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1.6.15 Antibody stainings for flow cytometry (for surface markers) 
After treatments, for harvesting, cells were washed with pre-warmed 1X PBS, and 
~1ml of detaching buffer was put onto cells and incubated on ice for ~10 minutes. 
Then, with gentle scraping and pipetting, cells were harvested, centrifuged at 3000 
RPM for 8 minutes. Supernatant was discarded. Cells were resuspended in FACS 
Buffer and divided to 0,5 ml eppendorf tubes for different stainings. Stainings were 
only CD11b, CD14, CD68 and a fraction of cells were left unstained. 
given in Table 2.16. 
1.6.16 Flow cytometry analysis 
Flow cytometry analyses were performed using BD accuri C6 software and FlowJo 
software. 
1.6.17 Densitometric analyses 
Densitometric analyses were performed to detect the densities of protein bands of the 
target proteins or to determine semi quantitative mRNA expression levels which are 
normalized to the density of housekeeping protein (GAPDH). Densitometric analyses 
were performed using Adobe PhotoShop CS5 Software. Densitometric values of 
bands were determined by multiplying index and mean levels of each protein band 
and these values were normalized to their corresponding housekeeping controls 
(GAPDH levels).  
1.6.18 Statistical analysis 
All p values were calculated using GraphPad Prism 5.0 software and determined by 
Student t test. In all analyses, a two-tailed t-test was applied and p-value of more than 
0.05 was considered statistically not significant. In column bar graphs, vertical bars 
indicate standard deviations of the mean, n.d. stands for not determined, and n.s. 
denotes not significant. 
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 RESULTS 
1.7 Expression of Chemerin in Gastric Epithelial Cells 
It was known from the literature that tumor epithelial cells secret chemerin [204,205]  
and increased plasma chemerin has been observed in gastric cancer patients [206]. 
To further understand the role of chemerin on gastric immune response to infection, 
firstly, the expression level of chemerin was investigated in three gastric epithelial 
adenocarcinoma cell lines, namely KATO III, AGS and MKN45. Conventional PCR 
results performed on these three cell lines revealed the presence of chemerin. 
Moreover, KATO III and AGS cells prominently express chemerin compared to 
MKN45 cell line as shown in figure 3.1. 
 
Figure 3.1 : Expression levels of chemerin in KATO III, AGS and MKN45 
cell lines performed by conventional PCR. RNAs were isolated from KATO-III, 
AGS and MKN45 cells (5×105 cells), converted to cDNA and Chemerin and 18S 
rRNA expression levels were investigated. Figure is representative of three 
independent experiments (n=3).  
1.7.1 Chemerin expression in H. pylori -treated gastric epithelial cells 
Various inflammatory disease models were shown to be closely associated with 
increased chemerin expression according to many literatures [48, 54, 57, 84]. 
Therefore, the expression status of chemerin on H. pylori induced gastric 
pathogenesis was evaluated. Firstly, the expression level of chemerin in KATO III 
and AGS cells treated with H. felis sonicate and various H. pylori sonicates, 
marker	 ctrl	 Plasmid	
				1	
Plasmid	
				2	
+	ctrl	
mRNA	Expression	
Hek293T	cells	transfected	
with	plasmid	
Exp	size	110	bp	
Protein	Expression	
Hek293T	cells	transfected	
with	plasmid	
Exp	size	18	Kd	
KATO III AGS MKN 45 
Chemerin  110 bp 
18s RNA 146 bp 
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including wild type G27 strain, along with its single virulence factors mutants, for 
example CagA deletion mutant G27-ΔCagA, PAI deletion mutant G27-ΔPAI and 
CagE deletion mutant G27-ΔCagE (Figure 3.2). As shown in the figure 3.2, the level 
of chemerin expression in H. pylori sonicate treated KATOIII (Figure 3.2 (A)) and 
AGS cells (Figure 3.2 (B)) was increased compared to their control groups. Elevated 
expression level of chemerin was more prominent in KATO III cell line, although 
both cell lines exhibited higher level of expression in wild type and ΔCagA treated 
samples. AGS cells did not show noticeable chemerin expression in G27-ΔPAI and 
G27-ΔCagE treated groups (Figure 3.2 (B)) as shown in densitometric analysis. As 
H. pylori virulence factor CagA was associated with the development of several 
gastric malignancies, the rest of the experiments were carried out using wild type and  
ΔCagA mutant sonicates. 
 
Figure 3.2 : Expression of chemerin in H. pylori sonicates -treated KATO III 
(A) and AGS (B) gastric epithelial cell lines. KATO-III and AGS cells were seeded 
on 6-well plates as 5×105 cells and each group was treated with 10 ug/ml of 
different helicobacter sonicates or left unstimulated (medium) for 6 hours. Then, 
cells were harvested and RNA isolations were performed. Following RNA 
isolation, they were converted to cDNA and analysed for Chemerin and 18S rRNA 
expressions using conventional PCR.   Densitometric analysis of chemerin was 
performed using ImageJ software. Images were prepared using Excel Office. All 
the graphs were normalized to 18S rRNA. Figure represents 3 independent 
experiments (n=3). 
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Next, we investigated quantitatively the expression levels of chemerin, in H. pylori 
sonicates (G27 wild type and its ΔCagA mutant) - treated KATO III and AGS cell 
lines in a time course experiment. The mRNA expression was significantly increased 
in both G27 wild type treated cell lines at 6 hours time point. The increased 
expression of chemerin was also detected at 24 hours time point in G27 wild type - 
treated KATO III cells (Figure 3.3 (A)), but not in AGS cells (Figure 3.3 (B)). No 
chemerin expression was detected in G27-ΔCagA -treated samples (Figure 3.3). 
 
Figure 3.3 : Expression of chemerin in H. pylori G27 WT and G27 ΔCagA 
sonicates -treated KATO III (A) and AGS (B) gastric epithelial cell lines. 5×105 
cells were treated with G27 wild type and G27-ΔCagA sonicates (10ug/ml) or left 
untreated (medium) for 6 and 24 hours. After that, cells were harvested and RNA 
isolations were performed. Isolated RNAs were converted to cDNA and evaluated 
for Chemerin and 18S rRNA expressions using qRT-PCR. Levels of 18S rRNA 
were used as endogenous control. Chemerin mRNA expression levels were 
normalized to endogenous control. Graphs were prepared with Graphpad Prism 6 
software. Statistical analysis was conducted using student’s t-test. The experiment 
was performed three times (n=3). 
 
62 
Moreover, the level of chemerin expression was assessed in gastric biopsies of 30 
patients with chronic ulcer and acute gastritis infected with H. pylori and compared 
to normal gastric tissue without any infection Interestingly, we have detected a 
significantly higher expression of chemerin in 10 ulcer samples when compared to 
gastritis and negative samples (Figure 3.4). Even though, more samples needs to be 
evaluated before coming to a conclusion, our result may suggest an association of 
chemerin with gastric pathology development.  
 
Figure 3.4 : Expression level of chemerin in 10 patients each with chronic 
ulcer and acute gastritis compared to 10 normal gastric biopsies (negative), 
evaluated by  real-time PCR. Levels of 18S rRNA were used for normalization. 
Graphs were prepared using Graphpad Prism 6 software. * represents p value less 
than 0.01. Statistical analysis was conducted using student’s t-test. Data is 
representative of two independent experiments (n=2).   
1.8 Chemerin Expression on Protein Level in Gastric Epithelial Cells 
After detecting increased expression level of chemerin in Helicobacter treated gastric 
cells, western blot was performed to investigate whether chemerin was also elevated 
on protein level in response to H. pylori treatment. Initially we evaluated levels of 
chemerin in whole cell extract and cell culture supernatants of KATO-III cells by 
western blot analysis at 6 and 24 hour time points (Figure 3.5). These time points 
were the ones that we detected the highest expression levels of chemerin in mRNA 
level. Chemerin is secreted as an inactive 18 kDa protein prochemerin, which 
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becomes activated by various proteases into isoforms of varying sizes, ranging from 
15 to 17 kDa [60-66]. 
Although, the expected size of chemerin in western blot analysis was between 15-17 
kDa, we did not detect any bands in that range. Interestingly,  prominent bands were 
observed on around 50 kDa. Initially it was thought the bands possibly represented 
another isoforms of chemerin or chemerin in a bound form. 
 
Figure 3.5 : Western blot was performed to assess protein level of chemerin in 
H. pylori G27 wt and G27-ΔCag A sonicate treated KATO-III cells at 6 and 24h. 
Cells were stimulated with H. pylori G27 WT sonicate and H. pylori G27 ΔCag A 
at 10 ug/ml final concentration or left untreated (medium) for 6 and 24 h. KATO-III 
cells were harvested for protein isolations and culture supernatants were aliquoted 
for detection of chemerin on SDS-PAGE. Cells were lysed and immunoblotted for 
membrane-bound chemerin (18 kDa). Supernatants were immunoblotted for soluble 
chemerin (18 kDa). GAPDH (37 kDa) and Ponceau S were used as loading control. 
Figure represents 3 independent experiments (n=3). 
However, all the isoforms of chemerin should be lower than 18 kDa size supported 
by numerous journals [88,207,208]. Repeated performance of western blot analysis 
of chemerin results into the similar outcome with no bands in the expected size. In 
order to investigat if antibody against chemerin detects any expected band, 
chemerin was cloned and transfected in HEK293T cells. Thereafter, western blot 
performed on HEK293T cells transfected with plasmid containing human chemerin 
gives bands at the expected18 kDa size (Figure 3.6 A). When we performed 
western blot analysis with Helicobacter -treated KATO III samples and chemerin 
over-expressed HEK293T cells together, band was only observed in the chemerin 
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over-expressed HEK293T cells. Similar results were observed in the western blot 
performed on AGS samples too (Figure 3.6 B). 
 
Figure 3.6 : Molecular cloning of chemerin using pCDNA3.1(+) plasmid was 
performed and transfected into HEK293T cell line (A). Western blot performed on 
the HEK293T protein lysates ensured the presence of chemerin on 18 kDa size. (B) 
Immunoblot was performed again using H. pylori G27 WT and G27-ΔCag A 
sonicate treated KATO-III and AGS cells at 6h and 24h along with the Chemerin 
expressing HEK293T protein lysates. GAPDH house-keeping proiten were used as 
loading controls respectively. Figure represents 2 independent experiments (n=2). 
We may conclude from our results that, chemerin protein level can not be detected in 
Helicobacter sonicate –treated gastric epithelial cells regardless of its elevated 
mRNA level.  
1.9 Immunohistochemical Analysis of  Human Samples with Ulcer and Gastritis 
Previously an elevated levels of chemerin mRNA expression was measured in 
patients with chronic ulcer biopsy samples. In order to investigate the levels of 
chemerin protein in biopsy specimens, as a preliminary study, we performed an 
immunohistochemical staining of chemerin on paraffin- embedded gastric tissue 
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sections of patients with acute gastritis and chronic ulcer (Figure 3.7). Even though, 
we experienced a high background staining with our chemerin antibody, we could 
detect a higher staining of chemerin in ulcer specimens compared to gastritis and 
normal gastric tissues. We performed our studies using both flourescence (Zeiss) and 
confocal microscopes (Leica).  
 
Figure 3.7 : Chemerin immunohistochemistry. Photomicrographs showing 
chemerin protein expression (green) in human gastric tissues collected from 
patients with H. pylori positive acute gastritis and chronic ulcer. Gastric tissue of a 
healthy individual was used as a control. Nuclear staining was obtained with 4,6-
diamidino-2-phenylindole (DAPI; blue) and pancytokeratin was used to stain 
cytokeratin proteins of epithelial tissues. Chemerin immunoreactivity was more 
prominent in ulcer tissues. Photographs were taken in Fluorescence (Zeiss Axiovert 
A1 Inverted) (A) and Confocal (Leica SP2 (B) microscope. The experiment was 
performed two times (n=2). 
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1.10 The Expression Level of Chemerin Receptor in Thp-1 and U937 Cells  
One study suggested that, chemerin stimulates macrophages to differentiate into M1 
subtype and elevates pro-inflammatory cytokines associated, while it inhibits M2 
differentiation in various disease models [86]. To further explore this hypothesis, 
recombinant human chemerin was used to test its effect on macrophages, with or 
without the presence of H. pylori sonicate. Two human monocytic cell lines, U937 
and THP-1 were initially sought for this purpose but as we did not detect expression 
of chemerin receptor in U937 cells, all the experiments were performed only on 
THP-1 cell line (Figure 3.8). 
 
Figure 3.8 : Chemerin receptor expression in PMA differentiated THP-1 and 
U937 macrophages. Conventional PCR revealed the presence of chemerin receptor 
in THP-1 macrophages only but no fchemerin receptor expression was observed on 
U937 differentiated macrophages. The experiment was performed two times (n=2). 
1.10.1 Monocytes to macrophage differentiation 
PMA (phorbol 12-myristate 13-acetate) was used to induce differentiation of 
monocytes into macrophages. PMA is an activator of Protein Kinase C (PKC) due to 
its structural resemblance to PKC activator diacylglycerol (DAG) and has a key role 
in monocyte adhesion. It exerts effect through inducing adherence and cell cycle 
arrest followed by differentiation of monocytes into macrophages via activation of 
PKC due to activation of transcriptional factors such as activator protein-1 (AP1), 
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resulting in the upregulated expression of cell adhesion receptors (β2-integrin 
family). Differentiated macrophages were further exposed to LPS and human 
recombinant IL4 to polarize them into M1 and M2 subtypes respectively, with or 
without the presence of chemerin. PMA differentiated macrophages were first 
analyzed for macrophage specific surface markers; CD11b, CD14 and CD68 by flow 
cytometer (Figure 3.9). 
 
Figure 3.9 : Percentages of PMA differentiated THP-1 macrophages.  Flow 
cytometry, dot blot graphs represents staining of approximately 5x104 with a 
specific macrophage marker, biotin-coupled anti-CD11b, PE coupled anti-CD14 
and biotin coupled anti CD-68 antibody (upper panel). Independent percentages and 
average percentage values are expressed as bar graph (Lower panel). Images were 
prepared using GraphPad Prism program. Data is representative of two independent 
experiments (n=2). 
All CD (Cluster of Differenttiation) surface markers were significantly upregulated 
in response to PMA stimulation compared to no PMA treated group. CD11b is an 
integrin family member that is expressed on the surface of both monocytes and 
macrophages and regulates leukocyte adhesion and migration to mediate the 
inflammatory response. Though it is not a specific macrophage marker per se , PMA 
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treatment significantly upregulated CD11b expression (76.6%) on differentiated 
macrophages detected by flow cytometer (Figure 3.9). 
CD14 is a specific macrophage marker that mainly detects bacterial 
lipopolysaccharide as well as other PAMPs. Significant upregulation was again 
observed on THP-1 macrophages, half of the population was found to be expressing 
CD14 on their surface, whereas 8.7% of unstimulated control cells (THP-I no PMA) 
were found to express CD14. CD68 is another monocyte/macrophage marker; it is a 
member of the lysosomal/endosomal-associated membrane glycoprotein (LAMP) 
family that binds to low-density lipoprotein. Flow cytometer analysis showed 32.8% 
population expressing CD68 over PMA stimulation compared to 8.5% on control 
population (Figure 3.9). All the data confirmed successful macrophage 
differentiation from monocytes. 
1.10.2 Effect of Chemerin on macrophage polarization 
After monocytes were differentiated into macrophages, they were further subjected 
to different stimuli to obtain M1 and M2 subtype with or without the presence of 
human recombinant chemerin. Briefly, macrophages were stimulated with 100 
ng/mL LPS to obtain M1 macrophages and 20 ng/mL recombinant IL4 to obtain M2 
subtype with or without 50 ng/mL recombinant chemerin. After cell harvesting, 
RNA was isolated and samples were converted to cDNA. M1 and M2 associated 
cytokines were measured by conventional PCR (Figure 3.10). 
IL1β and IL6 are two M1 macrophage associated pro-inflammatory cytokines and 
IL10 is a M2 macrophage associated anti-inflammatory cytokine. Conventional 
PCR analysis indicated increased IL1β expression in LPS treated samples with or 
without chemerin, rendering M1 subtype polarization. IL-6 expression was also 
observed in those samples. IL10 expression was only observed in recombinant IL4 
treated population. However, no IL10 expression observed when IL4 administered 
with recombinant chemerin, showing chemerin could potentially inhibit 
macrophage polarization into M2 subtype. This is also supported by other studies 
such as Lin et al where chemerin was detected to inhibit M2 associated genes in 
DSS induced colitis model. Although IL1β was elevated in response to LPS and 
chemerin stimulation but such effect was not observed on IL6 expression, which 
depicts that chemerin may not have potential effects on M1 subtype polarization. 
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Figure 3.10 : M1 and M2 specific cytokine expression in THP-1 differentiated 
macrophages treated with various stimuli, e.g LPS (100 ng/ml), recombinant IL-4 
(20 ng/ml) and recombinant chemerin (50 ng/ml) for 24 hours. After RNA isolation 
IL-1β, IL-6 and IL1-10 expression was observed by conventional PCR (A). 
Densitometric analysis of IL-10 (B), IL-1β (C) and IL-6 (D) was performed using 
ImageJ software. Images were prepared using Excel Office. All the graphs were 
normalized to 18S rRNA. Data is representative of three independent experiments 
(n=3).  
1.10.3 Effect of Helicobacter pylori and Chemerin on macrophage polarization 
Next, we investigated the potential effect of Helicobacter pylori on macrophage 
polarization. Briefly, PMA differentiated macrophages were treated with sonicates of 
G27 wild type and G27-ΔCagA with or without the presence of recombinant human 
chemerin for 24 hours. After incubation, RNA isolation was performed followed by 
cDNA synthesis. IL1β, IL-6 and IL-10 expression was determined by conventional 
PCR and normalized to 18s RNA (Figure 3.11).  
We did not detect any change of IL-1β expression in presence of H. pylori or 
chemerin stimulation as we show overall elevated expression in all samples except 
the control group. However, expression of IL-6 levels increased in all sonicate 
treated samples compared to the LPS group although such elevation was unaffected 
A) B) 
C) D) 
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by chemerin. This again support the idea that chemerin may not exert its effect on 
M1 type macrophage polarization (Figure 3.11). 
We detected a very low expression of IL-10 in the group treated with recombinant 
IL-4 with chemerin by conventional PCR (Figure 3.11 A). Moreover, we asssesed 
the expression level of IL-10 by real-time PCR.  
 
Figure 3.11 : M1 and M2 specific cytokine expression in THP-1 differentiated 
macrophages treated with Helicobacter sonicates along with various stimuli, e.g 
LPS (100 ng/ml), recombinant IL-4 (20 ng/ml) and recombinant chemerin (50 
ng/ml) for 24 hours. After RNA isolation IL-1β, IL-6 and IL1-10 expression was 
observed by conventional PCR (A). IL-10 expression was observed by RT pcr and 
graphs were prepared with Graphpad Prism 6 software (B). Densitometric analysis 
of  IL-1β (C) and IL-6 (D) was performed using ImageJ software. Images were 
prepared using Excel Office. All the graphs were normalized to 18S rRNA. Figure 
is representative of three independent experiments (n=3). 
Although, IL-10 expression was observed in treated groups, the expression was 
significantly reduced when chemerin was treated along with recombinant IL-4, 
suggesting the inhibition of M2 macrophages by chemerin (Figure 3.11 B). 
Interestingly, treatment of H. pylori sonicates triggered IL-10 expression which was 
slightly reduced with an addition of chemerin.  
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 DISCUSSION AND CONCLUSION 
During an inflammatory process, damaged tissues release mediators that contribute 
to the mounting of immune responses by regulating the trafficking of leukocyte 
populations. Chemokines and other chemoattractant molecules therefore play 
fundamental roles in the physiology of inflammatory events, as well as in the 
pathological dysregulations of these processes. Helicobacter pylori is a gram 
negative pathogen that resides in the human gastric epithelium and has been known 
for its association with severe gastric inflammation and malignancies, which 
ultimately leads to carcinoma. Chemerin is a 143 aa novel extracellular mediator, 
primarily known as a chemokine, is found in high amounts in various inflammatory 
diseases and expressed by many epithelial cells. However, its influence on 
Helicobacter pylori induced gastric inflammation is unknown. Therefore, we 
investigated the effect of chemerin which is potentially expressed and secreted by 
Helicobacter pylori - induced gastric epithelial cells. 
Macrophages are the members of the first line immune defence that can polarize 
according to stimuli and the local microenvironment and shape the local 
inflammatory status to adapt to outside stimuli. They express chemerin receptor 
CMKLR1 (also known as chemR23). They can be polarized into the classically 
activated -M1 type- macrophages and the alternatively activated -M2 type- 
macrophage subsets. It has been shown that H. pylori induces the expression of 
inducible NO synthetase (iNOS) from macrophages along with pro- inflammatory 
cytokines such as IL-6, IL-8, TNF-α, IL-1-β and M2 macrophages were detected in 
human gastric biopsy specimens from H. pylori positive individuals. Macrophage 
mediated pro-inflammatory Th1 and Th17 response was observed as the pre-
dominant adaptive response against H. pylori in humans. Chemerin was shown to 
suppress M2 macrophage polarization with increased pro-inflammatory cytokine 
profile in DSS induced colitis model in vivo and in vitro. Another study found 
increased chemerin expression on M1 macrophages with distinct IL-10 expression, 
explaining the inflammatory effect of chemerin on M1 macrophages. However, no 
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studies have yet investigated the effect of chemerin on the polarization status of H. 
pylori induced macrophages. Therefore, in this study, we investigated the effect of 
both chemerin and H. pylori on the monocytic cell line THP-1 and assess the 
differences on its polarization status according to cytokine profiles.  
In order to evaluate the effect of chemerin on gastric immunopathology, we first 
investigate mRNA expression level of chemerin in three gastric epithelial cell lines, 
KATO III, AGS and MKN45, by conventional PCR. Conventional PCR confirmed 
chemerin expression in all three cell lines, with comparatively less expression in 
MKN45 cell line. Next, we examine the expression of chemerin in KATO III and 
AGS cell line treated with different H. pylori sonicates, the wild type G27 strain and 
its ΔcagA, ΔcagE, ΔPAI mutant sonicates. We observed increased chemerin 
expression in the sonicate treated groups compared to control in both cell lines, 
which was more prominent in KATO III cell line. However, increased expression 
was observed only in wild type G27 and its ΔcagA mutant sonicate treated groups in 
AGS cell line. Since the H. pylori virulence factor Cag A (cytotoxin- associated 
gene-A) has been associated with the development of gastric malignancies as 
reported by many studies, we were interested to assess its effect on chemerin 
expression level. 
Real-time PCR was performed to study chemerin expression in KATO III and AGS 
cell lines treated with wild type G27 and ΔcagA mutant sonicate for 6 and 24 hours 
Chemerin expression was elevated after 6 hours of treatment with wild type G27 
strain sonicate in both cell lines. However, chemerin was elevated in 24 hour 
treatment with G27 wild type sonicate only in KATO III cells. Therefore, we 
presumed that chemerin may potentially have a role and associated with immune 
response in gastric epithelial cell lines which were infected with H. pylori strain. 
Infection with H. pylori has been one of the major reasons of developing gastritis and 
ulcer in humans [204]. In accordance with that, we have also checked chemerin 
expression in gastric biopsy speciments collected from patients with H. pylori  
infected chronic ulcer and acute gastritis and patients without pathology and 
infection. Chemerin was detected to be elevated significantly in ulcer patients 
compared to uninfected normal tissue. Interestingly, such increase was not detected 
in the gastric biopsy of patients with acute gastritis.  
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Next, western blot analysis was performed to investigate the level of chemerin 
protein upon H. pylori sonicates treatment. However, chemerin could not be detected 
by western blot in repeated attempts. Therefore, human chemerin was cloned, 
transfected into HEK293T cell line and immunoblot was performed. We observed 
chemerin by western blot in the chemerin-transfected HEK293T cell lines but not in 
other samples. Therefore, we presumed that, even if chemerin is significantly 
elevated upon H. pylori treatment on mRNA level, the protein level was not 
biologically significant enough to be detected by western blot. We also know from 
the literature that the various isoforms of active and inactive chemerin were present 
in different biological source [60-66]. So that, it could also be possible that the 
chemerin expressed in the KATO and AGS samples have undergone different 
proteolytic cleavage, forming different isoform of chemerin that probably lacked the 
epitope to be recognized by the antibody used for the immunoblot. Further 
experiments need to be performed to resolve this hypothesis. 
We showed previously that chemerin is highly expressed in inflamed gastric tissues 
of ulcer patients. As next, we performed immunohistochemistry to visualize the 
distribution and localization of chemerin in gastric specimens. 
Immunohistochemistry performed on paraffin embedded gastric tissue samples 
collected from H. pylori - infected patients of acute gastritis and chronic ulcer and 
patients who are not infected with no pathology . Similar to the mRNA expression, 
chemerin was shown to be highly expressed in gastric tissues of ulcer patients 
compared to tissues from gastritis patients and uninfected control.  
In order to understand the effects of chemerin on the polarization status of 
macrophages in vitro, a monocytic cell line THP-1 was used. In order to polarize 
THP-1 monocytes to macrophages, PMA (phorbol 12-myristate 13-acetate) was 
administered. Differentiation was checked by assessing expression of the cell surface 
markers specific for macrophages, such as CD11b, CD14 and CD68. PMA treatment 
significantly upregulated CD11b (76.6%), CD14 (50%) and CD68 (32.8%) 
expression on differentiated macrophages compared to monocytes The differentiated 
macrophages were then exposed to different stimuli such as LPS and recombinant 
IL-4 to polarize them into M1 and M2 subtypes respectively, with or without the 
presence of chemerin. Two pro-inflammatory cytokines, IL-1β and IL-6, were 
measured as markers for M1 macrophages. Both of them were significantly increased 
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in LPS- treated samples. When chemerin was administered with LPS, a significantly 
high expression of IL-1β and low expression of IL-6 observed when compared to 
LPS- treated sample only in the first experimental set. Therefore, initially it was 
thought that, chemerin might have a role in the polarization of M1 macrophages but 
repeated three experiments showed no difference in the expression of IL-1β and IL6 
in samples treated with LPS alone or with chemerin. This disprove our hypothesis 
that chemerin may have an effect on M1 polarization. IL-10 expression levels were 
assessed as a marker for M2 polarization. IL-4 treatment resulted in elevated IL-10 
expression compared to control group. When chemerin is added along with IL-4, IL-
10 expression significantly reduced. The similar effect of chemerin was also 
mentioned in the study performed by Lin et al. (2014) where chemerin reduced the 
expression of M2 associated genes. 
Next, we investigated the effect of H. pylori on the polarization of macrophages with 
or without the presence of chemerin to assess whether chemerin may alter the effect 
exerted by H. pylori on macrophages. The THP-1 macrophages were treated with 
wild type G27 and ΔcagA mutant sonicate with/without chemerin for 24 hours. The 
sonicate treatment polarized macrophages to M1 subtype with high expression levels 
of pro-inflammatory IL-1β and IL6 and also increased IL-10 compared to control 
group. The pro-inflammatory IL-1β expression was observed in the monocytes which 
is well recognized by the literature, since monocytes constitutively activate caspase-1 
which is necessary for IL-1beta processing and secretion, while macrophages require 
a second stimulus such as IL-4/IL-13 to activate caspase-1  [205,206]. 
M1 macrophages are known to produce IL-10 in response to bacterial stimulation, 
immune complexes and LPS [207,208]. This was also shown in a study on mouse 
macrophages which were treated by H. felis in our laboratory (unpublished data). We 
did not detect a prominent change of expression in IL-1β, IL6 and IL-10 when 
chemerin was added with sonicates. Therefore, our results suggested that, chemerin 
may not have a role on H. pylori induced M1 macrophage polarization. Moreover, 
IL-4 mediated M2 polarization was detected to be inhibited upon chemerin 
treatment. As IL-10 expression in the sonicate - treated group did not change in 
presence of chemerin, it could be said that these IL-10 was expressed by the M1 
macrophages and chemerin had no effect on polarizing or even changing the 
cytokine profile expressed by the M1 macrophages. 
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In conclusion, even though chemerin protein level could not be detected in gastric 
epithelial cells regardless of elevated mRNA expression, further investigation is 
required in order to understand and detect if different isoforms of chemerin are 
present. One plausible idea would be to detect chemerin protein using different 
antibody that recognize other epitopes present on the protein. Since chemerin is a 
secretory protein, identification of the protein level using chemerin specific ELISA 
can also deem logical. According to results found in RT-PCR and 
immunohistochemistry performed on human tissue samples, chemerin could have a 
role in the development of gastric pathology although further investigation should be 
carried out on more patients to confirm this preliminary finding. Our findings 
showed that chemerin did not affect the polarization of macrophages induced by H. 
pylori in vitro , this should be further investigated in animal studies, since in vitro 
studies may not always reproduce similar effects as observed in in vitro. As observed 
in the literatures, chmerin potentiate both pro [85] and anti-inflmmatory [79, 85] 
response through altering macrophage polarization conducted in animal study, this 
would be an interesting idea to detect chemerin’s effect on Helicobacter induced 
macrophage polarization status in animal models.  
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